Research Resources
Results
JDRF 2010 Annual Report
JDTable of Contents
Letter from Leadership
Research Milestones
Founder & Founding Members
Research Review 2010
Donor Support
Walk to Cure Diabetes
Gala
Corporate Partners
Major Donors & Partners
Beta Society Members
Stem Cell Research Fund
Named Grants
Financial Report
Chapters & Affiliates
Directors, Chancellors & Senior Staff
2
4
6
8
17
18
20
22
23
42
44
46
47
56
57RF
JDRF is committed to delivering better treatments – and ultimately a cure – to people with type 1 diabetes. Over its
40 years, JDRF has funded $1.5 billion in diabetes research –
more than any other charitable organization. It has become the
largest charitable funder of and advocate for type 1
diabetes research, setting the agenda for diabetes research
worldwide. In FY2010, JDRF funded more than $107 million in research
in 19 countries worldwide, including more than 40 human clinical trials – the final stage of research before
new therapies can reach the people who can benefit from them.
JDRF was founded in 1970 by the parents of children with type 1
diabetes and now has more than 100 locations around the globe. Our supporters share an unrelenting passion and
commitment to improving the lives of all people
with type 1 – and to one day achieving a world free of the disease.
research resources resultsRF
If the past 40 years have proven anything about type 1 diabetes research, it’s that meaningful progress is challenging, but achievable. And when a cure is finally found, JDRF will be the organization that has led the way, from the beginning.
One reason we can say this with confidence is that JDRF-funded research has advanced type 1 diabetes-related science significantly in these 40 years. We are the global leader in driving the translation of research progress into better treatments and an eventual cure for people with type 1 diabetes. Another reason is that 2010 was a pivotal year for achieving important milestones. We are on the cusp of tangible advances that will change the lives of people with type 1 diabetes.
One promising example is a study co-funded by JDRF in which researchers used a sophisticated nanotechnology-based “vaccine” to successfully cure and prevent type 1 diabetes in preclinical models. The study revealed important insights into how to stop the immune attack that causes type 1 diabetes, a critical step along the path toward finding a cure in humans. This approach is now being advanced for testing in people with type 1 diabetes as well as with other autoimmune diseases. You can read more about this study, and about other advances JDRF funding has supported, in the Research Review section.
The nanoparticle vaccine study is just one of many ways JDRF is helping to make progress toward our
fundamental goal of finding a cure. At the same time, we are working hard to gain new insights that can be used to drive the development of therapies to dramatically improve the lives of people with type 1 diabetes until that cure is found. We believe JDRF has an obligation to do all it can to reduce the day-to-day challenges of living with type 1 diabetes, as well as to reverse or even prevent its complications in the near term as we work toward our longer-term goal of a cure.
To ensure that we are allocating our funds to deliver both near-term benefits for people with type 1 diabetes and, ultimately, a cure, we have organized our research program efforts under two main areas: Treatment Therapies, to dramatically reduce the burdens of type 1 diabetes and its complications; and Cure Therapies, to bring about an end to type 1 diabetes once and for all.
Within the Cure area, the focus is on reversing or stalling the immune attack that causes the disease while simultaneously restoring independence from insulin therapy. Within Treatment, our efforts are centered around significantly improving the health and quality of life of people with type 1 diabetes. This new structure will enable us to further speed progress on initiatives with both nearer-term and longer-term projected benefits for us and our loved ones.
And there is good news to report on the fundraising front. Despite a tough economy, we enjoyed a return
Letter from Leadership
Lea
de
rs
hip
i
Jd
rF
02
Frank ingrassia Chairman, Board of directors
Jeffrey Brewer president and Chief executive Officer
More than 80% of JDRF’s expenditures
go directly to research and research-related
education.
RESEARCH RESOURCES
RES
ULT
S
to growth in public support in 2010. In fact, total public support grew by 8 percent from 2009, reaching $194 million. Overall revenues (public support plus investment income) grew to $207 million. This growth was driven by our core programs, such as the Walk to Cure Diabetes, which remains the backbone of JDRF’s fundraising efforts. Walks accounted for $76 million in fundraising support last year, making the JDRF Walk program among the largest and most successful in the world. Special Events and Major Gifts also helped raise support levels, as did fundraising by our International Affiliates.
We take this opportunity to extend our gratitude to our JDRF families, corporate partners, and volunteers, and our broader community of support, who help make our successes possible.
As we look to the future, we continue to grapple with the realities of this disease: millions of people suffer from diabetes and face the devastating complications that accompany the disease, including kidney and heart failure, blindness, stroke, amputation, and dangerously low blood sugar. These truths drive us passionately forward. We are encouraged by recent progress and the opportunities on the horizon. We remain focused on our mission. And we will continue to refine our strategy, as science and circumstance demand, to quicken the pace of meaningful progress and to drive research toward tangible and life-changing benefits for people with type 1 diabetes.
What will this involve?
It will require us to step up our collaborations with the biotechnology and pharmaceutical industry, with the goal of creating clearer paths toward the testing and approval of drugs and devices that benefit people with diabetes.
We will team up with other partners: doctors, nurses, diabetes educators, other foundations, governments, businesses, and scientists. We’ll also be enhancing our results-oriented oversight of the research we fund, creating metrics for success and timetables for progress, while achieving a level of transparency that enables us to drive research faster toward our goals.
What will not change is why we do all this: to dramatically improve the lives of people with type 1 diabetes in the near term; to prevent others from getting type 1 diabetes in the future; and to cure this disease as soon as possible.
A challenge, to be sure.
But with your continued support, we can and will remain true to our promise: to redouble our efforts, to secure all available resources for biomedical research, and to deliver a world without diabetes.
Thank you, as always, for all you do for JDRF and for everyone with type 1 diabetes.
Jdr
F i Lead
er
sh
ip
03
robert Wood Johnson iV Chairman of JdrF international
Mary Tyler Moore international Chairman
susan alberti aO hon LLd international patron
1970sJDRF (then known as the Juvenile Diabetes Foundation) is founded by Lee Ducat and parents of children with type 1 diabetes.
Vitrectomy, an early surgical technique to treat the progression of diabetic eye disease, is pioneered by doctors at a JDRF-funded ophthalmic research center.
Hormones that can beneficially alter the effect of insulin are discovered, purified, and synthesized. One of these, glucagon, becomes an important treatment for hypoglycemia.
JDRF scientists define the tumor angiogenesis factor, the abnormal growth of blood vessels in the eye caused by diabetes.
The first test to measure long-term blood glucose levels – the hemoglobin A1C test – is developed with JDRF backing. Thanks to this test, doctors and scientists can now determine how well someone is controlling diabetes over a period of months.
1980sJDRF-funded science leads to the development of genetically engineered insulin – the first human protein to be cloned and made by genetic engineering.
An experimental insulin pump is developed, delivering a pre-programmed flow of insulin, with larger amounts before meals.
JDRF scientists establish the relationship between low blood sugar and brain metabolism: since the brain cannot store glucose, it is particularly sensitive to rapid and prolonged hypoglycemia.
The relationship between diabetic eye disease and pregnancy is established – an important step in determining preventive measures. Diabetic retinopathy may progress during pregnancy and often reverses after delivery.
JDRF scientists find that blood sugar control is paramount to fetal development, leading to treatment standards that are invaluable to the delivery of babies by women with type 1 diabetes.
Researchers funded by JDRF advance understanding of the cells in blood vessels that are involved in the hardening of the arteries that can result from diabetes.
04
re
sea
rC
h M
iLe
sTO
ne
s
i J
dr
F
1990sTo prevent arteriosclerosis, scientists find that a prototype drug keeps glucose from blocking blood vessels and interacting with leaked plasma proteins.
JDRF research establishes the relationship between diabetic retinopathy and glycosylated hemoglobin levels.
The success rate of pancreatic transplants increases as scientists advance the procedures for transplanting a whole or partial pancreas.
JDRF makes islet transplantation a priority by establishing the JDRF Center for Islet Transplantation at Harvard Medical School, the first of many centers JDRF will launch that focus on reversing type 1 diabetes and hypoglycemic unawareness by replacing insulin-producing cells through transplantation.
JDRF establishes the Human Islet Distribution Programs to meet increased demand for insulin-producing cells for both clinical transplants as well as basic diabetes research.
2000 to presentJDRF helps establish the Immune Tolerance Network.
JDRF researchers develop the Edmonton Protocol for islet transplants, which uses less toxic immune-suppressing drugs.
JDRF partners with the Department of Defense to develop technology to monitor blood sugar.
JDRF research shows that the initial stimulus for diabetic eye disease comes not only from blood vessels but also from the nervous system and the neural components in the retina itself.
A JDRF-funded human clinical trial shows that treating newly diagnosed patients with a drug called an anti-CD3 antibody can preserve the function of insulin-producing cells for several years.
Military, government, academic, and industry researchers work together to develop better methods to deliver insulin and monitor glucose.
Research shows that insulin itself is a key target in the autoimmune attack on pancreatic beta cells.
Clinical trials use new technologies and treatments to reduce the risk of severe hypoglycemia in children.
A large genetics study shows that people with type 1 diabetes who carry a specific gene variant are protected to some degree from diabetic kidney disease.
Researchers discover that adult insulin-producing beta cells have the ability to successfully replicate.
Over 50 genes and genetic regions are identified as the genetic basis of type 1 diabetes.
JDRF-funded human clinical trials definitively show that people with type 1 diabetes who regularly use a continuous glucose monitor experience significant improvements in blood sugar control without increasing their risk for hypoglycemia.
Jdr
F i re
sea
rC
h M
iLes
TOn
es
05
I t was 40 years ago that Lee Ducat fainted upon
learning of her son Larry’s diagnosis of type 1
diabetes. Although devastated, the Philadelphia
mom and her husband, Edwin, were determined to
do all they could to help cure their son and others
with the disease. During a visit to Larry’s doctor
soon thereafter, Lee asked what it would take to
cure the disease. When the doctor replied “funding
for research,” the course was set. That same night –
May 21, 1970 – the Ducats hosted a cocktail party to
raise money for research – and JDRF was born.
That first year, Lee recruited a group of Philadelphia
area parents and guided them in raising $10,000 to
fund research – a triumph for the families who made
up what was then known as the Juvenile Diabetes
foundation (JDF).
Also in 1970, Lee teamed up with Senator Richard
Schweiker in an effort to gain governmental support
for a long-range plan to combat diabetes and
to establish research, treatment, and education
centers throughout the country. “I learned that you
could get more money for research in one day from
the federal government than you could get from
years of fundraising,” says Lee. The result was the
enactment of the first National Diabetes Mellitus
Research and Education Act.
In looking to grow the organization in order to
fund more research, Lee branched out, helping to
form chapters in Miami, Northern New Jersey, and
Washington by 1971.
In 1972, Lee took a step that would profoundly
affect JDF’s future: it was a phone call to New York
City mom Carol Lurie, whose son, Stephen, also had
type 1. Carol and her husband, Erwin, had formed
their own charitable group, bringing together
parents and grandparents of children with type
1 diabetes to raise money to fund research. With
these two charitable families coming together, the
mission of the foundation was set in full motion.
Through the early years of JDF, Lee and Carol each
served as President. Edwin was the first Chairman
of the Board, and took great measures to ensure
the foundation’s early success. Erwin followed suit
as third Chairman of the Board, and he and Carol
proved to be fierce advocates of expanding JDF’s
international presence – we now have affiliates in
Australia, Canada, Denmark, Germany, India, Israel,
Mexico, and the United Kingdom. The tremendous
work of these early leaders – as well as the endless
support and passion of a network of parents
nationally and internationally – have guided JDRF to
become the force it is today.
What started as a mother’s vision to help her
child has now evolved into the largest charitable
funder of and advocate for type 1 diabetes research
worldwide, with $1.5 billion funded in diabetes
research over the past 40 years. JDRF has helped
to ensure strong federal commitment to diabetes
science, and has become the leader in advancing
research toward better treatments and a cure for
people with type 1 diabetes. The foundation has
played a role in most of the advances that have
improved the lives of people with type 1 diabetes
over the past four decades.
A portrait of
Our Founder
and Founding
Members
If Not for Them...
06
Carol Lurie and Lee Ducat
FOu
nd
er
& F
Ou
nd
ing
Me
MB
er
s
i J
dr
F
recognIzIng40 Yearsof Progress
RESEARCH RESOURCES
RES
ULT
S
The hopes, dreams – and hard work – of our founder
and founding members pushed JDRF to expand
nationwide to over 100 chapters and around the
world to eight international affiliates. They shaped
JDRF in countless ways over the years. In recognition
of their vision and leadership, JDRF this year named
three of its highest organizational awards in their
honor: the Lee Ducat Chapter of the Year Award, the
Carol Lurie Affiliate of the Year Award, and the Erwin
Lurie Volunteer of the Year Award.
Sadly, Edwin and Erwin have passed on. However,
since there is still no cure for type 1 diabetes and its
complications, Lee and Carol are still fighting the good
fight, both serving on JDRF’s Board of Chancellors
and supporting the foundation in many ways.
Though Lee and Carol are still as committed as
ever to finding a cure, the scientific advances
over the past 40 years have made them realize
the importance of finding ways to improve the
treatment of type 1 diabetes in the near term.
“I believe that a cure is important, but so is the
amelioration of complications,” says Carol.
For Lee, there are three clear areas of type 1
diabetes research that she feels have made the
most progress in the past 40 years and that hold the
most promise for the future: prevention (possibly
through a vaccine), genetics (discovering new sub-
types of diabetes to allow for better diagnosis and
treatment), and stem cell research (to develop new
beta cells that can replace those destroyed by type 1
diabetes). She views these areas as pathways to the
ultimate goal of a cure.
“I’ve always likened it to a dart board,” Lee says.
“The more you throw the darts, the more likely you
are to hit the bull’s-eye.”
To help scientists speed progress, Lee also
founded the National Disease Research Interchange.
The organization provides scientists with ready
access to the biomaterials – human cells, tissues,
and organs – they need to investigate how diseases
like diabetes develop and progress and how
people who suffer from these diseases can be
treated and cured.
When she surveys the past 40 years of JDRF, Lee
believes that many things have changed – most
noticeably, JDRF’s size.
“But to me, we could never be big enough, because
the bigger we grow, the more darts we’ll have that
could hit the bull’s-eye,” she says.
Still, much about JDRF remains the same as ever,
Lee says.
“When I talk to parents and others deeply involved
at JDRF now,” says Lee, “they’re very much how I
was – love is what propels them day and night.”
Jdr
F i FOu
nd
er
& FO
un
din
g M
eM
Be
rs
07
Top left: Edwin Ducat, first Chairman of the Board. Top right: (Pictured left to right) Carol Lurie, Founding Member; Jacqueline Colvill of Houston, President of JDF, 1979; Lee Ducat, Founder; and Lester Salans, M.D., former Director of NIDDK, and member, first JDF Medical Science Advisory Board. Bottom left: Lee Ducat, Lester Salans, M.D., Carol Lurie. Bottom right: Erwin Lurie, third Chairman of the Board.
The hopes, dreams – and hard work –
of our founder and founding members
pushed JDRF to expand nationwide to
over 100 chapters and around the world
to eight international affiliates.
08
re
sea
rC
h r
eVie
W 2
010
i
Jd
rF
The past year was pivotal for JDRF research – both in numbers and in scientific focus. We funded$107 million in research, and we made significant advances toward new treatments and a cure for type 1 diabetes.
Moreover, as we marked JDRF’s 40th year, we passed a significant milestone, reaching $1.5 billion in cumulative research funding since our founding.
Jdr
F i re
sea
rC
h r
eVieW
20
10
09
That total is surely impressive, but it’s even
more so when put in historical context.
Consider that JDRF (then known as JDF) funded its
first research in 1974: four grants totaling just
over $200,000. Not until 1976 did the foundation’s
research funding surpass $1 million annually,
and as late as 1990, funding totaled just over
$16 million a year.
What this means is that the vast majority of the
$1.5 billion has come in just the last decade –
associated with achieving significant scientific
progress and exciting momentum, as exemplified
by the progress in the field of diabetes research in
the last year. It is thanks in large part to JDRF
funding that the field has blossomed over the past
10 years. New and highly promising areas of
investigation have emerged – beta cell regeneration,
autoantigen-specific immunoregulation, the
technologies that will allow for the development of
first generation artificial pancreas systems – that
were not even considerations a decade ago, let
alone back in 1970. JDRF has aggressively
invested in these areas and helped accelerate
these scientific advances.
Because of the momentum and developments
we have seen in recent years, JDRF remains as
confident as ever that continued funding of
innovative and critical research will result in
advances that will lead to better treatments
and ultimately a cure – and that we will be the
organization driving these developments.
At the same time, the past 40 years have shown
us that curing diabetes will not be easy. It has
become painfully clear that this is a highly
complicated disease, and to cure it, we must solve
multiple problems: We must figure out how to stop
the immune attack that causes diabetes; we must
determine how to regenerate or replace beta cells
so people can make their own insulin again; and we
must stop or reverse complications that may have
already begun.
research revIew 2010
JDRF funds research in
19 countries.
RES
EAR
CH RESOURCES RESULTS
We have come to believe that as we progress
toward these goals, it is vitally important that we
also focus on making life better for people with type
1 diabetes in the short term.
Without losing sight of the ultimate goal of a cure,
JDRF has turned some of its attention to areas we
believe will bring about impactful, tangible
improvements in the lives of people with type 1
diabetes in the near term – areas like achieving
better blood sugar control to protect against
complications. By doing so, we will help people with
diabetes live as long and healthily as possible as we
continue to search for a cure.
We have reorganized our research focus around
those two distinct, but related aims: science leading
to a cure, and science leading to better treatments.
This research review is organized in the same way,
highlighting progress across the past year in Cure
Therapies and in Treatment Therapies. We have also
expanded our Industry Discovery and Development
Partnership program to stimulate company
involvement in, and to support the commercialization
of, targeted type 1 diabetes research projects across
our research portfolio.
Throughout this review, there are common themes
that set JDRF research apart: our proactive
management of science, our ability to foster
collaboration and partnerships between academic
and industry researchers, our targeting of innovative
ideas, and our commitment to accelerating scientific
progress in the area of type 1 diabetes.
New and highly promising
areas of investigation have
emerged that were not even
considerations a decade
ago, let alone in 1970.
10
Cure-related research accounted for about
two-thirds of JDRF’s research funding in FY2010
and included programs and projects in our Beta Cell
Therapies and Immune Therapies portfolios.
Beta Cell Therapies research seeks to
find ways to restore the insulin-producing beta cells
that are lost in the immune system attack that
causes type 1 diabetes. Within this area, pathways
to a cure involve either the regeneration or the
replacement of the insulin-producing beta cells.
Regeneration focuses on triggering the body to
re-grow its own beta cells, and to convert or
reprogram other cells to become beta cells.
Replacement focuses on replacing lost or damaged
beta cells with functional beta cells or their earlier
cell forms from external sources, like organ donors,
animals, or stem cells. Last year, JDRF funded
approximately $35 million in research in this area.
Immune Therapies research seeks to
stop the immune system attack on beta cells that
leads to diabetes in the first place and destroys
newly regenerated or replaced beta cells if it’s not
addressed. Studies supported by the Immune
Therapies program focus on the discovery and
development of novel therapies for halting the
autoimmune response, with strong emphasis on
antigen-specific approaches. The Immune
Therapies program also supports studies to
understand the disease progression in individuals
at risk for type 1 diabetes as well as those with the
established disease – knowledge critical to the
ability to design and optimize immunotherapies at
all type 1 diabetes stages. In FY2010, JDRF funded
more than $32 million in Immune Therapies
research.
FY2010 Progress and Success
Immune TherapiesLong-Term Anti-CD3 Benefits A clinical trial in
Belgium found that a six-day treatment with an
anti-CD3 drug slows the progress of diabetes over
the first few years after diagnosis.
For many years now, JDRF has funded research into
the development of anti-CD3 antibody therapy –
CuRe TheRApIes
www.juvenation.org
re
sea
rC
h r
eVie
W 2
010
i
Jd
rF
Juvenation, JDRF’s online
community for people affected by
type 1 diabetes, has more than 12,000
members.
RESEARCH RESOURCES
RES
ULT
S
compounds engineered to block the function of the
T cells that mediate the immune system attack in
type 1 diabetes. The therapy has been shown to
halt the progression of diabetes in people newly
diagnosed with the disease. This study took that
work a step further by showing that even a brief
treatment at the time of diagnosis of type 1 diabetes
preserved the function of insulin-producing cells
for several years – a major step toward stopping
or slowing diabetes. The trial also pointed to the
importance of early intervention; people who
benefited most from the treatment were younger at
the time of diagnosis and had more remaining beta
cell function.
Phase III Trials Separate research on anti-CD3
treatments progressed to the most advanced stage
of clinical testing: Phase III trials.
Two of JDRF’s industry partners began testing
anti-CD3 treatments in Phase III trials. JDRF partner
MacroGenics and its pharmaceutical collaborator Eli
Lilly and Co. are evaluating the drug teplizumab in a
study of 530 people in 14 countries. JDRF partner
Tolerx and its pharmaceutical collaborator
GlaxoSmithKline are evaluating the drug
otelixizumab in two large Phase III trials at multiple
sites in Europe and North America. The trials
demonstrate the success of JDRF’s strategy to fill
gaps in the drug development pipeline by helping
small companies fund early clinical testing that then
attracts bigger companies to step in and fund the
large trials needed for FDA registration and approval
in the United States.
Recently, MacroGenics and Eli Lilly announced that
one of their trials of teplizumab used to treat
recent-onset type 1 diabetes did not meet its
primary efficacy endpoints during a one-year review.
The companies have decided to suspend further
enrollment and dosing in two other ongoing trials of
the drug in people with type 1 diabetes. This study
was not halted due to safety concerns. MacroGenics
and Eli Lilly are currently reviewing the data from the
trials to better understand the outcome and
determine next steps.
Advances Across Two Diseases JDRF joined
forces with two partners in an innovative bid to stop
the autoimmune dysfunction underlying both type 1
diabetes and multiple sclerosis. The program is
among the first between patient organizations for
different diseases.
JDRF has partnered with Fast Forward – the
drug-development arm of the National Multiple
Sclerosis Society – and Axxam, an Italian company
that is screening its extensive chemical library for
compounds that target immune system ion
channels – tiny tunnels on the surface of cells. It’s
believed that a particular ion channel is involved in
the immune system malfunction that causes both
diseases. With JDRF’s funding, Axxam is identifying
drugs that block the channel, and can be developed
as potential immune therapies.
11
A partnership Beyond ResearchNovo Nordisk
Thanks to Novo Nordisk, JDRF is now reaching people with type 1 diabetes in an entirely new way: via Juvenation, its online social networking site.
It all began in early 2008, when JDRF approached Novo Nordisk with the concept of developing a social networking site
for people with type 1 diabetes, particularly young adults and their families. Novo Nordisk liked the idea because it addressed a pressing problem that had recently been identified in a global survey of kids with diabetes: the lack of social and psychological support in healthcare systems, which resulted in poor disease control and increased risk for long-term health complications.
Novo Nordisk saw Juvenation as a way to address the problem. With its help, JDRF launched the site later in 2008, giving the world its first online social networking site designed for people with type 1 diabetes and their families to come together and share thoughts, tips, and concerns while learning and having some fun, too. By May 2010, Juvenation had reached the impressive milestone of 10,000 members, and it has kept growing by leaps and bounds, adding about 500 new members a month.
Novo Nordisk also collaborates with JDRF in other ways. For instance, it’s been a longstanding supporter of the Ride to Cure Diabetes, sending 26 riders – including President and CEO Lars Rebien Sorensen, an annual participant – to the Death Valley Ride in 2009.
Jdr
F i re
sea
rC
h r
eVieW
20
10
12
Nanoparticle Vaccines Researchers successfully
cured and prevented type 1 diabetes in mice using
an innovative nanotechnology-based vaccine.
JDRF-funded scientists used a vaccine made of
nanoparticles – thousands of times smaller than the
size of a cell – that were coated with proteins
involved in enabling immune cells to communicate
with one another. The treatment increased the
numbers of a type of cell that suppresses the
immune system attack underlying diabetes, and
restored normal blood sugar levels in mice with
the disease. The study, conducted at the University
of Calgary in Alberta, provides important insights
into stopping the immune attack that causes type 1
diabetes. In fact, these discoveries have now
triggered the formation of a company called Parvus
Therapeutics, Inc., which will further develop the
technology. The study also shows the potential of
antigen-specific therapies, which target highly
specific autoimmune responses without damaging
the overall immune system.
Blocking “Natural Killer” Cells Scientists
demonstrated that certain immune system cells
(called regulatory T cells) play a role in preventing
type 1 diabetes.
Researchers at Harvard Medical School showed that
regulatory T cells control how diabetes progresses
in mice. The cells rein in the immune attack on the
pancreas by changing how other immune system
cells – called “natural killer” cells – function. When
there were no regulatory T cells to block them, the
natural killer cells began the immune attack that
causes diabetes. The research suggests that drugs
or therapies targeting these cells could prevent
diabetes or alter its course.
nPOD Expands to Europe JDRF’s nPOD program,
a remarkable success in advancing research into the
causes of type 1 diabetes, was expanded to Europe.
The Network for Pancreatic Organ Donors with
Diabetes – better known as nPOD – provides
diabetes researchers worldwide with access to
pancreatic and other tissues from organ donors at
all stages of diabetes; researchers use the tissues in
studies that seek to answer key questions about the
underlying cause and characteristics of type 1
diabetes. By expanding to Europe, nPOD can offer
researchers an additional pool of potential organ
donors – including the important but less-studied
group with pre-diabetes, a stage of disease prior to
insulin-dependence. nPOD expects to be screening
about 30 percent of all organ donors in the United
States by the end of 2011 – a key milestone for the
program, and a huge help for researchers.
Beta Cell TherapiesRegeneration Partnerships JDRF entered into
three new partnerships to speed the fast-developing
field of regeneration, demonstrating its leadership
in this new and highly promising pathway of
diabetes research. The early-stage research driven
by JDRF has now attracted the attention of large
pharmaceutical companies who are committing
funds and capabilities to accelerate drug
development for beta cell regeneration. JDRF will
continue to explore innovative partnerships and
new funding mechanisms to address gaps in type 1
diabetes research.
• A research collaboration with Pfizer, Hadassah
Medical Organization, and The Hebrew University
of Jerusalem to develop drugs that can regenerate
insulin-producing cells. The program evaluates
Pfizer compounds that promote cell regeneration,
and builds on unique beta cell regeneration
models created by JDRF-funded researchers.
• A unique agreement with the Genomics Institute
of the Novartis Research Foundation (GNF) to
create a drug discovery and development platform
for beta cell proliferation, survival, and
reprogramming. This is one of the largest and
most comprehensive collaborations in JDRF’s
history, and marks a major opportunity to work
with an experienced and highly regarded scientific
partner to quickly translate discoveries in research
into new therapies.
• A collaboration with the Johnson & Johnson
Corporate Office of Science and Technology to
develop drug targets and pathways that promote
The past 40 years have shown us that
curing diabetes will not be easy. This is a
highly complicated disease, and to cure
it, we must solve multiple problems.re
sea
rC
h r
eVie
W 2
010
i
Jd
rF
JDRF is now funding more than 40 trials
in people.
RESEARCH RESOURCES
RES
ULT
S
beta cell survival and function. The program funds
research at academic and medical research
centers worldwide, creating an “incubator” to
support early-stage studies. By working with a
company known for first-class research and
significant experience in the commercialization of
products, JDRF is looking to increase the number
of viable drug targets identified and fundamentally
advance the pace of diabetes research.
Pancreas Cells Change into Insulin-Producing Cells (Reprogramming) Researchers at the University of Geneva in
Switzerland showed that pancreas cells that do not
normally produce insulin hold the potential to
naturally convert into cells that do.
In research in mice, alpha cells in the pancreas –
specialized cells that produce glucagon, not insulin
– can spontaneously convert into insulin-producing
beta cells under specific conditions. The study
showed the potential of these cells to adapt and
produce insulin when needed – in this case, when
the beta cells that normally produce insulin were
destroyed. The results were the first to show that
beta cell reprogramming can occur spontaneously,
without genetic manipulation; scientists may be
able to harness this conversion potential to
regenerate beta cells in people with diabetes. This
may be particularly useful in people who have had
diabetes for a long time and have no, or very few,
remaining beta cells.
Critical Beta Cell Development Gene Identified Scientists identified a gene needed
for cells to mature into insulin-producing cells and
other cell types in the pancreas.
Researchers from the University of California,
San Francisco and McGill University showed that
mice lacking a certain gene were not able to make
insulin-producing cells (or most other cells in
the pancreas). They also found that in people,
newborns who had a deficiency of that gene
eventually developed diabetes. The research
provides important new insights into beta cell
development. Most importantly, it boosts the
prospects for one day being able to generate an
abundant, renewable supply of insulin-producing
cells to replace those killed off by the immune
attack that causes diabetes.
Stress Hormone Linked to Cell GrowthA hormone responsible for the body’s stress
response was linked to the growth of insulin-
producing cells, suggesting new pathways to
restore beta cells and cure diabetes.
When researchers at the Salk Institute for
Biological Studies in California exposed beta cells
to a stress hormone and high levels of sugar, the
cells began to replicate. The findings reinforce the
potential of regeneration as a cure for diabetes, and
provide insights for discovering new approaches to
treat the disease.
13
Jdr
F i re
sea
rC
h r
eVieW
20
10
Mom Leads her hometown to Walk for a CureLisa TaylorThere’s no JDRF chapter in Fredericksburg, VA; the nearest one is a 45-minute drive away in Richmond, the state capital. But that hasn’t stopped local mom Lisa Taylor from building a highly successful Walk in her hometown.
Lisa helped spearhead the creation of the Fredericksburg Walk after moving there from New York City, where she had connected with JDRF after her daughter Elissa was diagnosed with type 1 diabetes at 10 months old. In New York City, Lisa had helped make the Queens Walk a success. After the family moved to Fredericksburg, Lisa got involved in a local type 1 support group for families, and together, some of the parents decided to hold a Walk to raise money for JDRF. That first year, they gathered at the city’s historic Civil War battlefield site and raised $3,000.
The founding families sought out the support of JDRF’s Central Virginia Chapter in Richmond the following year, and Lisa took on the role of volunteer Walk chair. She steered the Fredericksburg Walk to steadily growing success. But after five years in the role, Lisa was finding the job tough, given medical issues she was experiencing at the time. She thought about stepping down.
Then her second daughter, Genaya, was diagnosed with type 1 diabetes at the age of 14 in December 2007. Lisa quickly banished all doubts about continuing in her Walk role. The event has continued to go from strength to strength under her guidance. With her daughters’ help – Elissa is now a 20-year-old college senior and Genaya is a 17-year-old high school senior – Lisa organized the most successful Fredericksburg Walk ever this past year, raising more than $40,000.
Lisa has no intention of stopping now. “As a parent, you want to do anything in your power to help your children,” she explains. “I believe we can get to a cure, and I will do whatever it takes to help us get there.”
Treatment-related research accounted for
one-third of JDRF’s research funding in FY2010
and included programs and projects in our Glucose
Control and Complications Therapies portfolios.
JDRF’s Glucose Control program
encompasses research designed to produce drugs,
devices, and products that can help people with
diabetes better manage their disease. Glucose
Control research is still in its infancy at JDRF, but
over the past five years, JDRF has sped to the
forefront of this area of science, thanks largely to its
Artificial Pancreas Project – a cross-functional effort
to speed the development and use of automated
and semi-automated systems to sense blood sugar
and dispense insulin in response. In FY2010, JDRF
Glucose Control research totaled an estimated
$22 million, approximately 90 percent of which
was committed to various aspects of the Artificial
Pancreas Project.
Complications Therapies research
includes science aimed at preventing, slowing, or
reversing the major complications of diabetes: eye
disease, kidney disease, nerve disease, and
cardiovascular disease. JDRF has been particularly
focused on eye disease, with several major advances
in the past year that are bringing new treatments for
macular edema and retinopathy. In FY2010, JDRF
funded more than $17 million, with approximately
40 percent spent on diabetic eye disease.
FY2010 Progress and Success
Complications TherapiesFirst New Diabetic Eye Disease Treatment in 25 Years A groundbreaking study identified the
first new treatment for people with diabetic eye
disease in the last 25 years. The results show it not
only stops the progress of eye disease, but
improves vision – a huge step up from any other
treatment now available.
The study, a Phase II clinical trial, showed that the
drug Lucentis, when combined with the current
standard treatment of laser therapy, not only slows
the progression of diabetic eye disease but can also
14
17 Years of the paper sneakerTops Friendly Markets and JDRF
The JDRF Sneaker is a well-loved symbol of JDRF’s Walk to Cure Diabetes – and the focus of a nationwide Sneaker Sales campaign that raises $10 million a year for type 1 diabetes research. Like many great fundraising ideas, this one came from a JDRF supporter – namely Tops Friendly Markets, the supermarket chain based in Williamsville, NY.
The Sneaker Sales concept was born in 1993, when JDRF approached Tops about developing a fundraiser for that year’s local Walk to Cure Diabetes. Larry Castellani, then President and CEO of Tops, agreed to sell a dollar item in stores for six weeks leading up to the Walk. With the help of Doug Hartmayer, Tops’ community relations director, creative juices began to flow between Tops and JDRF, and they finally settled on printing cut-out paper footprints to sell to customers for a $1 minimum donation. The program was a big success, so they decided to repeat it the following year. But this time, they thought footwear was more apt than footprints – and designed the paper Sneaker that we all know and love today. Other JDRF chapters caught wind of the idea, and the fundraiser started to grow.
“We became very attached to JDRF,” Hartmayer recalls. “They energized us, and we energized them. They weren’t just asking a corporation to do something; they were there with their sleeves rolled up working side by side with us.”
Since the program’s inception, Tops has raised more than $6.7 million for JDRF. In acknowledgement of the company’s generosity over the years, JDRF recognized Tops at its 2010 Annual Conference in Washington, DC.
Tops’ 132 supermarkets throughout New York and Pennsylvania run fundraisers all year long to support JDRF – everything from bowling events to spaghetti dinners – but the Sneaker program remains the company’s top fundraiser, says Andy Brocato, Hartmayer’s successor, who has been involved with the program at Tops for 13 years.
The company’s commitment remains as strong as ever.
“Our greatest accomplishment has not been achieved yet,” Brocato says. “Our job is to put JDRF out of business. One day we’ll be at your going-away party.”
That’s one “threat” worth celebrating.
TReATMeNT TheRApIes
re
sea
rC
h r
eVie
W 2
010
i
Jd
rF
Is proudly supported by: Is proudly supported by: Is proudly supported by:
15
actually improve vision. The breakthrough is the
result of JDRF research investments over many years
in partnership with Johns Hopkins University School
of Medicine and Genentech, which licenses Lucentis.
Eye Drops for Macular Edema A clinical
trial found that a topical drug slows the progress
of a severe form of diabetic eye disease called
macular edema. Because this potential treatment
can be self-administered, it may also ease the
burdens of healthcare costs and be more readily
used by patients.
Diabetic macular edema is a leading cause of
blindness in adults with diabetes. Researchers at
the Wilmer Eye Institute of Johns Hopkins University
School of Medicine last year completed a multi-
center clinical trial evaluating mecamylamine,
a topical drug developed by JDRF industry partner
CoMentis, Inc. About 40 percent of the people in the
trial showed significant improvement, including in
vision, after using mecamylamine eye drops.
Gene Therapy for Nerve Damage The Phase
III trial of a gene therapy developed by JDRF industry
partner Sangamo BioSciences showed that the
therapy reverses and repairs diabetic nerve disease.
The trial tested a gene therapy to treat nerve
damage in the legs of people with peripheral
sensory neuropathy (a common diabetic
complication that involves small nerve fibers in the
arms and legs, often leading to a loss of sensation
and motor function). The study showed that the
drug can help re-grow nerves by promoting the
production of a specific protein linked to nerve
growth and function. An increase in these proteins
may protect the nerves and repair nerve damage
in people with diabetes. This would be a major
improvement, since current treatments address
only the pain associated with neuropathy.
Glucose ControlArtificial Pancreas Partnerships JDRF’s
Artificial Pancreas Project established several
partnerships with key industry participants to drive
the development of a system to enable people with
type 1 diabetes to achieve tighter blood glucose
management, lead healthier lives, and reduce their
risk for complications.
JDRF entered into an innovative, non-exclusive
partnership with Animas Corp. to develop a
first-generation artificial pancreas – an automated
insulin delivery system – to help people better
control their diabetes. Animas is a Johnson &
Johnson company and a leading pump
manufacturer. JDRF also announced a partnership
with BD (Becton, Dickinson and Co.), aimed at
developing new insulin delivery products to
enhance insulin pumps. Advances in pump
technology will not only lead to improved glucose
control but can also be incorporated into an
artificial pancreas. The partnerships were dramatic
steps on the road to producing a readily available
artificial pancreas.
Avoiding Overnight Lows A first-generation
artificial pancreas showed that it can safely
control the blood sugar of children and teenagers
with diabetes overnight – the most frightening
time for children, teens, and their parents because
of the danger of unrecognized and untreated low
blood sugar.
In a landmark study in children and teenagers with
type 1 diabetes, JDRF researchers at the University
of Cambridge showed that using a first-generation
artificial pancreas system overnight lowers the risk
of low blood sugar emergencies while improving
diabetes control overall. The system maintained the
blood sugar of the participants in safe and healthy
ranges throughout the night, even under a number
of differing conditions and situations, such as after
they had eaten a particularly large dinner or after
they had exercised.
It is vitally important that
we also focus on making life
better for people with type 1
diabetes in the short term.
Jdr
F i re
sea
rC
h r
eVieW
20
10
JDRF has committed more than $70 million to research at 29
companies through its Industry Discovery
and Development Partnership
program.
RES
EAR
CH RESOURCES RESULTS
16
CGM, Insulin, and Glucagon Researchers
showed that an artificial pancreas system could
successfully integrate hormones like glucagon –
underscoring its potential to replicate all the
functions of the pancreas.
Researchers from Boston University and
Massachusetts General Hospital showed that an
artificial pancreas using two hormones – glucagon
as well as insulin – can lower the risk of low blood
sugar emergencies. Glucagon is a naturally
occurring hormone that counters insulin’s action;
it raises blood sugar when people experience
dangerously low blood glucose levels, or
hypoglycemia. The production of glucagon is
impaired in people with type 1 diabetes. Using an
insulin-plus-glucagon version of the artificial
pancreas, all study participants achieved near-
normal blood sugar levels for more than 24 hours
without experiencing hypoglycemia.
CGM Studies Show Benefits of Regular Use
Researchers confirmed that regular CGM use – six
days per week or more – is the most important factor
in achieving better diabetes control; less important
is the age of the person using the monitor or other
demographic, clinical, or psychosocial factors. A
second JDRF study found that people who continued
using a CGM were able to sustain good control
long-term while experiencing a lower rate of
hypoglycemia, a state of dangerously low blood
sugar that can occur even with tightly managed
type 1 diabetes.
The research underscored the point that CGMs are
more than simply devices of convenience for people
with diabetes – they are tools that can substantially
improve blood sugar control in people of all ages
when used regularly, without increasing the risk of
dangerous low blood sugar. The growing evidence of
CGMs’ benefits highlights the need for continued
research into a closed-loop artificial pancreas, a
system that uses CGM data to automatically deliver
the right amount of insulin at the right time.
pedaling with a purposeJDRF Ride to Cure Diabetes
The JDRF Ride to Cure Diabetes engages bicyclists from around the world to take on two challenges: raising the money needed to fund the research for better treatments and a cure for diabetes; and reaching a personal training goal to prepare them for a destination cycling experience.
JDRF Ride destinations are designed for riders of all fitness levels. JDRF supports riders in each challenge; connecting them with both a USA Cycling certified coach and a JDRF fundraising coach. At each site, riders have professional mechanical support as well as ride support on a well marked and marshaled course. Clinics and training rides precede the Ride, and evening awards dinners recognize the amazing accomplishments of the families and friends that support JDRF’s Ride to Cure Diabetes. The program has raised more than $20 million since its founding in 1998. Last year’s program attracted more than 700 participants from all over the
world to Rides in five spots: Killington, VT; Kansas City, MO; Whitefish, MT; Death Valley, CA; and Tucson, AZ. More than 70 percent of participants in the Ride return each year, raising on average $4,500 each and proving that the experience is both rewarding and life-changing.
Over the past five years,
JDRF has sped to the
forefront of glucose
control research, thanks
largely to its Artificial
Pancreas Project.
“ I have had type 1 diabetes for 39 years, and after completing my first Ride, I felt as if I had just accomplished more than any other single thing I had ever done. That was nine Rides ago. I was hooked; it’s changed my life forever, and I won’t stop riding until there’s a cure.”
– Lorne Shiff Toronto, Canada
re
sea
rC
h r
eVie
W 2
010
i
Jd
rF
As many as 3 million
Americans have type 1 diabetes.
RESEARCH RESOURCES
RES
ULT
S
17
Jdr
F i dO
nO
r s
up
pO
rT
DonorsUPPorT
18
At the very core of this paramount level of achievement is everyone who helps in the Walks’ success, especially the passionately dedicated family and corporate teams.
Every JDRF Walk also creates a special kind of support beyond the dollars raised. Walkers whose lives have been touched by type 1 diabetes come together, building a sense of community and purpose that far surpasses any price.
We are delighted to recognize the family teams that raised $75,000 or more for the Walks in FY2010. These teams listed represent only some of
the countless devoted family and corporate teams, walkers, donors, and volunteers who contribute to the enormous success of the more than 225 Walks held each year.
JDRF’s Walk to Cure Diabetes program is in a league of its own, having raised over $1 billion toward our mission since the program began in 1992, including $86.1 million in FY2010 alone.
dO
nO
r s
up
pO
rT
i
Jdr
F
walk To cUre DIabeTes
The kids at Mesa Middle School in Castle Rock, CO, had a lot to be proud of last year. Working together, they helped their school become the No. 1 online fundraiser
nationwide for the Kids Walk to Cure Diabetes program. Their final tally: more than $13,800 raised online (and more than $18,900 raised overall).
The Mesa students achieved their gold-medal performance by making full use of the new tools launched in 2010 as part of the Kids Walk to Cure Diabetes website. For example, they created personal webpages and e-mailed friends and family asking for support.
The Kids Walk site also provided teachers with lesson plans and educational activities to help students learn more about diabetes and JDRF. It gave families and school personnel tips for making their Walk a success.
English/language arts teacher Katherine Azofeifa led the effort at Mesa and was deeply touched by seeing the kids taking steps – literally and figuratively – to help each other. The Mesa middle schoolers proved that “Kids Helping Kids” isn’t just a motto for the Kids Walk program, but a reality, too.
Congratulations to the FY2010 Family Walk Teams who raised more than $75,000!
Kids Walk Website Takes program to the Next LevelMesa Middle School
Cohn Sisters: Mackenzie’s Miracle Makers & Sydney’s Superstars Eastern Pennsylvania/Delaware Chapter
Team Cure New England/Bay State Chapter
Michael’s Legal Eagles New York City Chapter
Joe’s Impatient WalkersGreater Bay Area Chapter
Tessa’s Troopers Los Angeles Chapter
Punkin’s PeepsNew York City Chapter
Team SudburyNew England/Bay State Chapter
Harmelin Family TeamEastern Pennsylvania/Delaware Chapter
Lizzie’s CrusadersMetro-St. Louis/Greater Missouri Chapter
Mimi’s MarchersLong Island Chapter
McFeeley MarchersCharlotte Chapter
Team JakeTampa Bay Chapter
Charlie’s AngelsLos Angeles Chapter
19
nearly 40 years later, the Cohns were again tapped to help ensure the
success of a JDRF Gala in Philadelphia, serving on the “honorary committee” that helped fundraise for the Eastern Pennsylvania/Delaware Chapter Gala in May 2010. But this time, they had a highly personal reason for volunteering their time: their granddaughters, Sydney and Mackenzie. The girls were both diagnosed with type 1 diabetes at the age of seven and a half – Sydney in the winter of 2007 and Mackenzie in the summer of 2008.
Since the girls’ diagnoses, the entire extended Cohn family has gone all-out to do what Norman and Suzanne helped do in JDRF’s early days: raise money to fund research toward better treatments and a cure for all who live with type 1 diabetes.
Matthew and Lea Cohn, the girls’ parents, say the family is made up of the kind of people who, when faced with a challenge, ask themselves: “What can we do to make things better?”
That philosophy is reflected in the enormous success they’ve had in raising money to fund diabetes research. The family’s Walk team, known as “The Cohn Sisters: Mackenzie’s Miracle Makers and Sydney’s Superstars,” has been the No. 1 family team for three years running now. This past year, the team’s 200 walkers raised nearly $330,000 – putting them over the $1 million mark cumulatively to date.
What’s the secret to their success? “Reaching out to people,” says Matthew. “We ask everybody, all the time. We let people know that we are raising money for diabetes research, and we focus on making sure people are aware.”
The Walk has become an integral part of their lives. “One of the most important things about the Walk is the sense of hope it gives us – and the feeling that we can make a difference,” Lea says.
The Cohns do far more than just participate in the Walk, however. Matthew serves on the Eastern Pennsylvania/Delaware Chapter Board and is a recent addition to JDRF’s International Board of Directors. Both Matthew and Lea serve on their chapter’s Gala and Walk committees. They have donated the leadership “patron gifts” to their local Gala every year since 2007, and they have enlisted the rest of their family members – grandparents, aunts, uncles, cousins – in the cause of raising money for research. As if all that weren’t enough, Matthew recently also took on the role of National Walk Chair.
Matthew and Lea are happy to commit their time to JDRF. For one thing, they credit JDRF with giving them crucial support when their daughters were diagnosed. “There was a time when I could not envision our lives ever being normal again,” Matthew says. But he began to see “the light at the end of the tunnel,” as he called it, when a JDRF family invited the Cohns to their home. “When we went to their house, everything was so normal. It helped me see that our lives could be normal, too.”
Most importantly, Matthew and Lea give their time and treasure to JDRF because they know that their daughters have
benefited from research made possible by those who came before them – including Lee Ducat and Matthew’s parents, Norman and Suzanne. They want to honor those contributions by making their own.
“We are indebted to Lee and to all the other volunteers who came before us,” Lea says. “The research that they helped make possible has made the disease much more manageable.”
Matthew agrees: “We are truly the beneficiaries of all that JDRF has done throughout the years. Today, there is so much promise, so much hope. This is going to be the first chronic disease to be cured. I’m sure of it.”
“ One of the most important things about the Walk is the sense of hope it gives us – and the feeling that we can make a difference.”
Jdr
F i dO
nO
r s
up
pO
rT
hope is a Cohn Family TraditionBack in 1971, JDRF was still a fledgling organization, and founder Lee Ducat was working tirelessly to raise money for research. To help plan a Gala for the new Philadelphia-based foundation, she turned to two friends – Norman and Suzanne Cohn – to chair the event. The Cohns had no personal connection to type 1 diabetes; they just wanted to help.
COhN family
20
gALA
Today, JDRF hosts more than 95 Galas nationwide – attracting over 44,000 people – each year. The Galas provide a fun, elegant evening filled with dinner, cocktails, entertainment, and silent and live auctions. Gala evenings are highlighted by JDRF’s signature Fund A Cure, a live auction which has raised more than $140 million for diabetes research since it began in 1994.
Each Gala has its own honoree(s) (an individual, couple, family, or business), who not only give generous support of their own,
but also bring in additional support from people they know. At the Gala, JDRF recognizes the honoree(s) – celebrating their efforts and the progress they’ve helped make toward better treatments and a cure.
We are pleased to recognize here the honorees who helped lead their chapters in raising more than $100,000 through the FY2010 Galas. Our thanks goes to these special supporters and to all the honorees, supporters, and volunteers who make JDRF Galas so successful and inspirational.
Started in communities around the country long ago, JDRF’s Gala program officially launched in FY2000. The program has raised over $450 million since its inception, with $52 million raised in FY2010 alone.
dO
nO
r s
up
pO
rT
i
Jdr
F
Advance Auto Parts Team Members, Customers & Vendor PartnersAdvance Auto PartsGreater Blue Ridge Chapter
Citlali & Fernando AguirreGreater Cincinnati Chapter
Amy & Jared AllenKansas City Chapter
William Danforth Metro-St. Louis/Greater Missouri Chapter
Richard & Karen DavisCapitol Chapter
Al de MolinaGMACCharlotte Chapter
Suzy Doherty, Managing Director & Sean Doherty, General CounselBain CapitalNew England/Bay State Chapter
Lee Ducat & Good Neighbor PharmacyDiabetes ShoppeEastern Pennsylvania/Delaware Chapter
John & Debbie EckFairfield County Chapter
Jay Fishman, Chairman & CEOThe Travelers Companies, Inc.North-Central Connecticut/Western Massachusetts Chapter
Founding FamiliesGreater Dallas Chapter
The Hendren Family (Eileen, Mike, Ruth & Charles Hendren)Triangle/Eastern North Carolina Chapter
Darren Jackson, CEO; Mike Norona, CFOAdvance Auto PartsMinnDakotas Chapter
Pitch & Cathie Johnson Asset ManagementGreater Bay Area Chapter
Gregory B. Jordan, Global Managing ParnterReed Smith, LLPWestern Pennsylvania Chapter
Sandra E. Peterson, Executive Vice PresidentBayer HealthCare, LLCNew York City Chapter
Nina & Mitchell Quaranta; Louise & Terrance GreggLos Angeles Chapter
John Reisman Jack Parker Corporation John CammettAerotermFlorida Suncoast Chapter
Arthur & Nancy RothNortheastern New York/Capital Region Chapter
Renee West, PresidentMandalay Bay Resort & CasinoNevada Chapter
Dr. & Mrs. Byron Williams (Living & Giving Awards)PricewaterhouseCoopersGeorgia Chapter
JDRF has more than
100 locations worldwide.
RESEARCH RESOURCES
RES
ULT
S
21
Jdr
F i dO
nO
r s
up
pO
rT
eight years ago, Fernando Aguirre, Chairman and CEO of Chiquita Brands International, Inc., was flying to Europe
with his wife, Citlali, and sons, Franco and Fabrizio. Suddenly, Fabrizio became violently ill. Being unable to do anything about it was traumatic, recalls Fernando. When the plane finally landed, the family rushed Fabrizio to a hospital, and it was there that they learned he had type 1 diabetes.
The Aguirres turned to friends and acquaintances to introduce them to other families affected by type 1 diabetes. It wasn’t long before they heard about JDRF. “We got high recommendations for JDRF, and that’s how we began to connect with the organization,” Fernando explains.
Yet to say that the Aguirres “connected” with JDRF is quite an understatement. They have been more than just generous donors and extremely involved volunteers. They are a family that has repeatedly given far more than what’s asked of them, while continuously thinking “outside the box” to come up with novel ways to benefit JDRF.
As Gala chairs in 2007 and honorees last May, the Aguirres are true champions for their Greater Cincinnati Chapter Gala. In addition to donating approximately $100,000 annually to the Gala alone, they put their hearts into it as well. During his acceptance speech at the chapter’s 2010 Cincinnatians of the Year Gala, Fernando spoke about the great research progress being made and the hope for a first-generation artificial pancreas in the near future. To help illustrate the potential of an artificial pancreas, he asked Fabrizio to do a “show-and-tell” of sorts – to lift his shirt and let the attendees see his continuous glucose monitor and insulin pump – both of which are key components of an artificial pancreas.
Bill Rice, the chapter’s Executive Director, says, “The Gala had incredible energy in the room, in large part due to the Aguirres.” Thanks significantly to the Aguirres’ involvement, the Gala was named best non-profit event in the Cincinnati community by the city’s Business Courier newspaper.
Fernando, who is chairing the Finance Committee on JDRF’s International Board of Directors for a second year and serving on the Executive Committee for a third year, has also brought his company into the cause. Chiquita hosted a golf tournament, the Chiquita Classic, on this year’s Nationwide Tour, with JDRF as one of the main beneficiaries.
Always paving new paths of generosity, the Aguirres have recruited close family friend Dhani Jones, a linebacker for the National Football League’s Cincinnati Bengals, to join them in a number of efforts benefitting JDRF. Fabrizio, now 18, collaborated with Dhani in designing a bow tie that initially sold for $57 (57 being Dhani’s jersey number), with all proceeds going to the chapter. Due to their enormous popularity, the bow ties originally produced – along with 75 extras made to meet the overwhelming demand – ended up being auctioned off for $100 each at the 2010 Gala. The Aguirres also donated a unique item to the Gala’s auction: an authentic Mexican dinner (cooked entirely by Citlali) for 20 people at the Aguirres’ home with Dhani as a guest – and including a promise that Dhani would visit the attendees’ kids at their schools. What anyone else would view as tremendous generosity Fernando views as common sense. As he says matter-of-factly: “The more you put in, the more you get out.”
Thanks significantly to the Aguirres’ involvement, the Gala was named best non-profit event in the Cincinnati community by the city’s Business Courier newspaper.
AguIRRe familyRedefining generosity: Aguirre Family goes Above and Beyond
22
CORpORATe pARTNeRs
hy-Vee helps support Research to Make Life “easier, healthier, and happier” for people with DiabetesHy-Vee
Hy-Vee, the employee-owned Midwestern grocery chain, says its aim is “Making lives easier, healthier, and happier.” One of the best examples of its delivery on that goal is its longstanding support of JDRF. Hy-Vee has been a steadfast JDRF supporter for 12 years now, contributing more than $10 million to research toward better treatments and a cure for people with type 1 diabetes.
How has Hy-Vee achieved so much? Each year, the
company holds a JDRF Sneaker Sales campaign with wrap-around events at many of its more than 230 grocery stores. Hy-Vee also sends a large group of employees, both current and retired, to participate in the Ride to Cure Diabetes program each year.
Hy-Vee is dedicated to serving the needs of local communities. In its eight-state region, Hy-Vee is very active at the local JDRF chapter level. The company’s employees serve on several chapter Boards, while forming teams for their local Walks and sponsoring/attending their local Galas. Moreover, through its in-kind donations of food, beverages, and giveaways for JDRF events, Hy-Vee helps JDRF to keep expenses at a minimum – meaning more dollars for research, and more potential for improving the lives of people with type 1 diabetes.
Corporations partner with us in a number of ways,
including Corporate Signature programs, the Walk
to Cure Diabetes, the Ride to Cure Diabetes, Galas,
retail promotions (namely paper Sneaker Sales),
golf events, and our Major Donor program.
Overall, Corporate contributions for FY2010 brought
in over $60 million to JDRF, which enables us to
continue finding and funding gaps in diabetes
research worldwide.
We deeply value our Corporate Partners and we are
pleased to recognize those partners that contribute
over $1 million annually and those honored at our
Annual Conference:
$2 Million Plus Partners
$1 Million Plus Partners
JDRF 2010 Annual Conference Award Recipients
Innovation Award: Novo Nordisk
Reaching New Heights Award: Build-A-Bear Workshop & Medtronic Diabetes
Chancellors’ Award: Roche Diabetes Care & Accu-Chek
Chairman’s Award: Ford Motor Company
President’s Award: Advance Auto Parts
JDRF Corporate Partners represent companies that truly understand and support our mission. We are proud to partner with many companies both nationally and internationally.
dO
nO
r s
up
pO
rT
i
Jdr
F
MAJOR DONORs & pARTNeRs
23
$3,000,000 and aboveAdvance Auto Parts
Ford Motor Company
The Leona M. & Harry B. Helmsley Charitable Trust
$1,000,000 - $2,999,999Hy-Vee, Inc.
Kellogg Family Foundation
Marshalls
Roche Diabetes Care
Walgreens
Lisa and Neil Wallack
$500,000 - $999,999Anonymous (1)
Estate of Jeanne Avegno
Delta Airlines, Inc.
Genentech, Inc.
Hille Foundation
Medtronic Diabetes
The O. Wayne Rollins Foundation
Estate of Lisl Schuhmann
Stop and Shop
Tops Markets, LLC
$250,000 - $499,999Mary and Dick Allen in Honor of Hannah
Cash America International, Inc.
Discover Financial Services
Tim and Lisa Fleet
The Fresh Market
Estate of Howard Halff
Judy and Walt Havenstein
Estate of Diane Hoag
Hurlbut-Johnson Charitable Trusts
Charles and Ann Johnson
Lipsig Family Foundation
McDonough Foundation
Novo Nordisk Foundation
Silpada Designs, LLC
The Collis/Warner Foundation, Inc.
$100,000 - $249,999Anonymous (6)
Advance Stores Company, Inc.
Allscripts
Bayer Diabetes Care
Becton Dickinson & Co.
Josh and Anita Bekenstein
The Benaroya Company
Bridget and Mike Bender
Fran and Bruce Bergman
Bloomingdale’s, Inc.
Jennifer Bolt
Boston’s Pizza
Mark, Valerie and Jason Brodsky
Buford Family Foundation
Build-A-Bear Workshop Foundation
Estate of Meade and Herbert Bynum
Carolina Restaurant Group
Casey’s General Store
Mr. Albert Chan
Cisco Systems, Inc.
Clear Channel Outdoor
The Coca-Cola Foundation
The Cohn Family Foundation
Mr. and Mrs. Matthew Cohn
Community Health Charities of Nebraska
Estate of Charles M. Conlon
The Cooper-Siegel Family Foundation
Cordeck’s Cruise for a Cure
Cordick Sales
Karen and Richard Davis
Al and Donna de Molina
Dr Pepper Snapple Group
Edward Jones
Ericsson
The Fine Family – Team Brotherly Love
Ashley and Michael Fisher
Ford KTP Cares
FOX 25
Larry and Charlotte Franklin
The James A. Gammon Charitable Foundation
GoDaddy.com
The Gregory Fund
Estate of Arthur Guarino
Harman Management Corporation
Karen and Cliff Harris
Harry S. Moss Heart Trust
Holmes Murphy
The Howard Family Foundation
Insulet Corporation
Solomon Jackson, Jr.
Jensen Charitable Lead Annuity Trust
Ron Jensen Charitable Lead Annuity Trust
Stacey and Dave Johnson
Jonas Brothers’ Change for the Children Foundation
Don and Donna Kelleher
Kirkland & Ellis, LLP
In Honor of Krista Klopp
Kohl’s Department Store
The Komar Family
John and Connie Kurkowski Family
Lakeside Industries
JDRF expresses its deep appreciation to the friends and partners who have so generously invested in our core programs. The people, corporations, and organizations listed below helped advance research toward better treatments and a cure by making an outright gift or pledge of $10,000 or more in FY2010.
Jdr
F i dO
nO
r s
up
pO
rT
JDRF has received an
“A” rating from the American Institute
of Philanthropy for 11 straight
years.
RES
EAR
CH RESOURCES RESULTS
Lasseter Family Foundation
Jonathan and Jeannie Lavine
The Lehto/Virga Family
LifeScan, Inc.
Eli Lilly and Company
The Lincy Foundation
Estate of Elmer Livingston
The Karen and Herbert Lotman Foundation
Boston Marriott Copely Place
The Meyer Charitable Foundation
Nationwide Foundation
Novo Nordisk
Michelle Griffin and Thomas Parker
Mr. and Mrs. Richard C. Patton
Pella, Inc.
Pioneer
QUALCOMM Incorporated
Quick Chek Food Stores
Republic Finance
The Partners of Ropes & Gray, LLC
Estate of Brenda Rudnak
Russell Stover Candies
Sage Hospitality Res.
Sanford Health
Janet and Flip Short Family Charitable Fund
Anonymous - In Memory of Carolyn H. Taylor
Tetco
Texans Credit Union
Texas Instruments
Travelers Foundation
Glen and Trish Tullman
Turner Broadcasting System, Inc.
Eve and James Tyree
USA Drug Stores
Ms. Hilary Valentine and Mr. Don Listwin
Virginia Mason Medical Center
Vivian and Louis Vance
Wawa, Inc.
Sharyl and John Weber
$75,000 - $99,999Anonymous (1)
Carolyn and Kenneth Aldridge
Aldridge Electric
BP America
Mr. and Mrs. John Cammett
Marci Eisenstein and John Treece
Gilbert and Jacqueline R. Fern Foundation
George Polli Foundation
Gordmans, Inc.
Estate of Joanne Gorman In Memory of Cynthia Ann Hawkins
Patty and Kenneth Halverson
Mr. and Mrs. William Fred Hagans
Hess Corporation
Estate of Bernard Jaffee
Mr. and Mrs. Donald Jones, Jr.
D. Scott and Pamela Kroh
Kum & Go
Lunds & Byerlys
Monica Maliskas
Medtronic Foundation
Amy and Alan Meltzer
The Neilan Foundation
Old Orchard
Melitta S. Pick Charitable Trust
PPD
RR Donnelley
Arthur and Nancy Roth
Pamela and William Sagan
David and Janelle Shaffer
Mr. and Mrs. Morton Silver
The TJX Foundation, Inc.
Estate of Freda Watts
Yum Brands, Inc.
$50,000 - $74,999Anonymous (3)
AAR Corp.
Abbott Diabetes Care
Aimbridge Hospitality
Alpine Children’s Charity
Mr. and Mrs. Neal Allen
Estate of Robert D. Allen
Estate of Helene Alley In Memory of Theodore Whitlock and Theodore Whitlock, Jr.
Steve and Lisa Altman
Amgen
The James Annenberg La Vea Charitable Foundation
Aon Risk Services Northeast, Inc.
Asset Management Company
Bank of America
Lynda and Chris Barnes
Ann and Sam Barshop, Colleen and Bruce Barshop and Jamie Barshop
The Barstein Family via The Birmingham Jewish Foundation’s JDRF/Israel Fund
BB&T
Michael and Carolyn Bealmear
Big Y
Blackbird Technologies, Inc.
BLMF
Blue Cross Blue Shield of Georgia
BP Lubricants USA, Inc.
Roy and Vanessa Carroll
Dr. Carol Cheney and Dr. Josh Bardin
Chubb Group of Insurance Companies
CIGNA
Coca-Cola Enterprises
Elsie T. & Josephine Colombo Charitable Trust
Community Health Charities of Illinois
Robert Compton
Mr. William R. Conley, Jr.
Cravath, Swaine & Moore, LLP
CSX Transportation and Friends
Cushman & Wakefield
Henry D’Auria
Sean and Suzanne Doherty
Arnold Donald and Family
R.L. Donald, Jr. Family Trust
Ed Miniat, Inc.
Sandy and Paul Edgerley
Ernest Lieblich Foundation
Christine and Larry Fee
Mr. and Mrs. Alan Fisher
Ford Sharonville
Laura L. and Robert T. Fraley
The Franke Family
Estate of George T. Gorman In Memory of George and Pearl Gorman
Granite Properties
Guilford Foundation
Rita Haddow
Harris Teeter, Inc.
The Haun Trust
H-E-B
Edward Heil
Michael and Eileen Hendren
High Points Auto Insurance
Hopkins Capital Group II, LLC
Howard Industries, Inc.
Jansen Family Foundation
24
MaJOr dOnOrs & parTners continuedd
On
Or
su
pp
Or
T i
Jd
rF
285 million people worldwide have
diabetes; by 2030, it’s predicted that
435 million will have the disease.
RESEARCH RESOURCES
RES
ULT
S
25
w hen Bob and Joan Lipsig’s three-year-
old daughter, Lynn, was diagnosed with type 1 diabetes nearly 40 years ago, her future looked bleak. They were told her life expectancy would be only about 30 years.
After looking at several organizations for support, they learned about a new one called the Juvenile Diabetes Foundation. They were drawn to this newcomer, because unlike any of the others, it was actually searching for a cure. The Lipsigs decided to connect with the foundation’s chapter in Chicago – and that was the beginning of a long and fruitful partnership.
Bob says it was JDRF’s professionalism that convinced them to dedicate their time and money to the organization.
“Obviously for our daughter, we needed to do whatever we could to make her situation better,” he says. “But I think what probably swayed me the most, in terms of getting involved, was the analytical business approach that JDRF took toward the research.”
Joan says she threw herself into volunteering for JDRF once Lynn graduated from high school and left for college. She and Bob served on the chapter’s Board, doing whatever was asked of them. “The chapter had a great cadre of people, and it was almost a family kind of a mission,” Bob says. “We shared each other’s traumas and trials and tribulations.”
By the early 1990s, the family’s resources from their business – manufacturing and importing sporting goods and children’s licensed products – had grown to the point where they could begin making consistent, if not “significant” donations to JDRF, Joan says.
“We’re not in that million-dollar class of people; we’re just those middle-class people who just keep trodding along,” she says. “It takes all of us to do our job. We’re all important in our own way; we all contribute and do what we can.”
In addition to their own generosity, they also helped JDRF raise funds from others. Bob signed on as a Board member for
JDRF’s first international capital campaign. At the time, JDRF was pioneering interdisciplinary research, bringing together a variety of research specialties as the best chance of finding a cure.
“I think that really got my attention,” Bob says, “because as opposed to just throwing a lot of money at certainly a worthwhile cause, we were
approaching it from a very systematic way, evaluating our investment and constantly insisting that the recipients of our funds were made to account for it.”
The Lipsigs definitely feel that their investment has paid off. Lynn, now 41, is a consultant with a midsize consulting group in Chicago (and herself a former Board member of the Illinois Chapter). Bob and Joan credit research advances with helping their daughter remain healthy well past the life expectancy originally forecast for her. For example, they say the landmark Diabetes Control and Complications Trial, funded in part by JDRF, convinced Lynn to achieve tight blood glucose control to reduce her risk for complications. They also point to advances in retinal surgery as having saved Lynn’s eyesight.
They are undaunted by the fact that the cure has not yet been found. “We’re not bitter we haven’t cured it; we’re just thankful our daughter Lynn has been able to live as quality a life as she has, with a good hope of living a long and normal life in later years,” Bob says. “That, to me, is critical.”
Says Joan, “We really feel that there’s a chance out there. You can’t give up; science takes time. When Lynn was diagnosed we were doing urine test strips, which were about as accurate as nothing! So think of that, the progress that’s been made.”
Nearly Four Decades of supporting JDRFL I psIg family
Their message to other families is to focus on the advances that have already been made, while continuing to consistently support research. They have not given up hope for a cure.
Jdr
F i dO
nO
r s
up
pO
rT
Johnson & Johnson
Johnson Controls
Pitch and Cathie Johnson
JP Morgan Chase
Joanne Kagle
Mr. and Mrs. John Kampfe
Dusty Elias Kirk and William R. Caroselli
Barbara Kouris
Estate of Dorothy F. Krause
Estate of Erwin Levy Kremen
Kroger
Kenneth and Jennifer Kroner
Sandra L. Kurtzig Foundation
Ladd and Hogue Trust
Pat and Frank Liberto
LIUNA
Madden Charities, Inc.
Jade and Mark Matlock
Phyllis McGovern
Estate of Ruth McLaughlin
Matthew Meister
Shannon and Bart Millard
Monsanto
Mr. and Mrs. Leo Mullin
NBC Universal
Debbie and Stephen Newman, M.D.
Myron Noble
In Memory of Kevin Christopher Nolan
Nordstrom
Northwestern Mutual Financial Network
George L. Ohrstrom, Jr. Foundation
Orkin
Ms. Jane Parker
Permatex, Inc.
Plaza Marketing Associates, Inc.
The PNC Financial Services Group
Point of Hope, a Deron Williams Foundation
Estate of Jean Pond
Thomas and Stella Press
Steve and Cindy Rasmussen
The Reynolds Company
Estate of Earl and Laurel Rogers
Marlene and Bruce Saltzberg
Renee and Robert Samuels
Saturday Club of Wayne, PA
Denise and Marc Schmittlein
Robert and Candi Selig
Sequent Energy
Sonora Quest Laboratories
Estate of Carol Sorensen
Standard Motor Products
Michael and Debora Sullivan
Estate of Bettie W. Sumara
Swat-Fame, Inc.
Taylor Family Foundation
Tesoro Corporation
Thinkway Toys
UnitedHealthcare
Richard and Marie Unnerstall
University of Pittsburgh Medical Center
Utah Angels
Vintage Hollywood
Wells Fargo
Williams Trading, LLC
The Woodbury Foundation
$25,000 - $49,999Anonymous (7)
3M Corporation
7UP
Abby’s Friends Foundation
Abbott Fund
AC Delco
Accenture, LLP
Diane Adams
Amy and Micah Adams
Aetna, Inc.
AGL Resources
Airtex Products, LP
Akin Gump Strauss Hauer & Feld, LLP
Albertsons
Alcoa Foundation
Amy and Jared Allen
Allstate Giving Campaign
Ally Bank
Alpine-Litho Graphics
American Legion Child Welfare Foundation, Inc.
Amylin Pharmaceuticals, Inc.
Michelle and Richard Anderson, M.D.
Anheuser-Busch Companies
The Annenberg Foundation
Anthem Blue Cross
Arch City Theater Troupe
Mr. and Mrs. Jeff Arnold
AT&T
Charles F. Avery
B&D Industries, Inc.
Cathy and Rick Baier
Bain Capital Children’s Charity
Baker Hughes
Bank of New York Mellon Asset Servicing
Barbara Davis Center for Childhood Diabetes
Barclay’s Capital
Ann K. and G. Kenneth Baum
BBB Industries
BBDO
BBH
BD Technologies
Belk, Inc.
Toni and Steve Berlinger
Junior Beta Clubs of Louisiana
BKD Foundation
Blank Children’s Hospital
Blue Cross Blue Shield of Mississippi
Bluegreen Corporation
Christopher Bolt
Bombardier Aerospace Corp.
Bon Secours Richmond Health System
Bosch
Bosch (Purolator)
Bill and Ute Bowes
Kara and Kevin Boyle
Tony and Amy Briney
Brinton Eaton
The Brockriede Family
Kate and Peter Brown
Terry and Cindy Brown
BTIG, LLC
Mr. and Mrs. J. Mahlon Buck, Jr.
Betty Burnham
Edward L. Calcaterra
Mitchell and Cindy Caplan
Francois and Laura Cardinal
Carl M. Freeman Foundation
Margo and John Catsimatidis
Cellino & Barnes
Cenegenics Medical Institute
Cereal Food Processors, Inc.
The Rhoda and David Chase Family Foundation
Chevron
Bill and Kim Chisholm
26
MaJOr dOnOrs & parTners continuedd
On
Or
su
pp
Or
T i
Jd
rF
The Ride to Cure Diabetes
in Killington, VT raised $1.4 million in FY2010 — more than any Ride in
JDRF history.
RESEARCH RESOURCES
RES
ULT
S
27
Cia Centro Inspection Agency
Emory T. Clark Family Charitable Foundation
Clark Construction Group, LLC
Brett and Karen Coleman Foundation
Cooley Godward Kronish, LLP
E.L. Cord Foundation
Laura and Kelly Crain
Credit Suisse
Crowley Automotive Group
Mark Curry
CVS Caremark
Dade County Federal Credit Union
D’Agostino Supermarkets, Inc.
Danaher Tool Group
The Dash to Cure Diabetes, Inc.
DCP Midstream
Cathy and Alex Debelak
Arlo and Barbara DeKraai
Denso Sales
Diabetes Shoppe
DIRECTV, Inc.
Dobbs Tire & Auto Centers
Barbara and Peter Dyson
Norman Eaker
East Penn Manufacturing
John and Debbie Eck
Bill and Barbara Edwards
Electronic Tax Center
EMWIGA Foundation
Energizer Holdings, Inc.
Kim and Peter Enns
Entergy
Brady Exber
Exelon Corporation
Cindy and Robert Fairchild
Federal Home Loan Bank of Atlanta
Federal Mogul
Judy and Richard Feldstein
Domenic and Molly Ferrante
Fidelity Charitable Gift Fund
Fifty 50 Pharmacy
Fifty 50 Medical Devices, LLC
First Community Bank
First National Bank
Mark and Lisa Fischer-Colbrie
Randy and Jay Fishman
Flextronics
Thomas J. Fogarty, M.D.
Harrison Ford and Callista
Flockhart
The Henry Ford II Fund
Ford Louisville Assembly Plant
Franklin Templeton Investments
Mr. and Mrs. Gregg Freishtat
Patricia and Steven Gabbe
Barbara M. Gasser
GEICO
Genpact
Joanne Gimbel
Glen Cove PBA
David Glick
GMB North America, Inc.
Mr. and Mrs. Seth Godin
Goldberg, Kohn, Bell, Black, Rosenbloom & Moritz, LTD
Beth Kreeley Goldstein and Dennis Goldstein
Good Times Burgers
Eunice and Douglas Goodan
Mike and Becky Goss
Estates of John R. and Elaine B. Grady In the Name of Timothy Richard Grady
Grant Thornton, LLP
The Graves Foundation
SL Green Realty
Greenberg Traurig, LLP
Terry and Louise Gregg
David P. and Toni Halle, Jr.
Donald and Nedra Hansen
The Stephen P. Hanson Family Foundation
H. Edward and Ellen Hanway
Alice and Raymond Hartke
Brad and Kim Hayes
Hayes + Associates
HealthTrust Purchasing Group Tees Up for Kids
Henry Schein, Inc.
Highmark Blue Cross Blue Shield
Kathy and Jim Hipps
Hoffman Car Wash and Jiffy Lube
Tim Hoiles and Lorie Mondo
Honeywell
Hope For A Cure Guild
Sam and Anne Hummel
Imagine a Cure
Indianapolis Marriott Downtown
International Association of Heat and Frost Insulators & Allied Workers
Intricon Corporation
Jacks Family Restaurants, Inc.
Mr. and Mrs. James Jacobson
JDRF North Iowa Volunteers
Jewelers Charity Fund For Children
Robert Wood Johnson Foundation
Karen and Jeffrey Jordan
Gregory and Ellen Jordan
Kaiser Permanente
Edward and Irene Kaplan
Michael Keaton
Bonnie and Jerry Kelly
Jdr
F i dO
nO
r s
up
pO
rT
giving You Can Cuddle up To Build-A-Bear Workshop
Last year, Build-A-Bear Workshop decided to turn its special expertise toward a new kind of building project: namely, building support for JDRF among its guests.
During its annual retail campaign supporting JDRF, Build-A-Bear Workshop initiated a point of sale donation collection program in all U.S. stores, requesting a $1 donation from every customer at the time of checkout. At its Canadian stores, Build-A-Bear offered the company’s signature purple satin hearts to customers for $1.
Customers responded to these innovations with great enthusiasm, enabling the Build-A-Bear Workshop Foundation to deliver almost $209,000 to JDRF in 2009 – a nearly 575 percent increase over the previous year’s total!
Build-A-Bear Workshop has been a JDRF corporate supporter since 2003, generating more than $400,000 for diabetes research in that time. The partnership stretches from local to national levels: the company hosts local events in support of JDRF at its World Bearquarters in St. Louis, and holds its nationwide retail fundraising campaign each November in conjunction with National Diabetes Awareness Month.
28
MaJOr dOnOrs & parTners continued
How has Steve Winer made a difference in the lives of thousands of people with type 1 diabetes?
He helped create the Online Diabetes Support Team, a volunteer group that answers all kinds of questions about the disease from people all over the world. In the process, he helped establish a role for outreach at JDRF.
Q
A
The story begins back in 1997. At that time, the Internet was still
a relatively new phenomenon for most people. But not for Steve, who was then working for a small Internet service provider on Long Island and well-versed in all things Web.
When Steve’s daughter, Allie, was diagnosed with type 1 diabetes that year at the age of 11, Steve used his Internet savvy to do some research online, and ended up connecting with other parents through message boards and chat rooms – including Ardy Johnson of Seattle, whose son had type 1 diabetes. Steve learned about JDRF and connected with his local Long Island Chapter.
Soon thereafter, JDRF’s national office asked Steve to share his expertise by joining its volunteer-led Information Technology Committee. At the time, JDRF’s website was “young and incomplete,” and committee members were grappling with questions like “what do we need to do with this
Internet stuff?” as Steve recalls. He and others saw great potential to using technology to support the JDRF mission.
Steve and Ardy championed the idea of establishing JDRF as the “go-to place” for people needing information and advice; they decided to create an “online support team” of volunteers – people who had “been there, done that,” as Steve puts it. The team would provide crucial support by answering people’s questions – submitted via the JDRF website – about living with type 1 diabetes.
With Steve and Ardy spearheading the effort, the “Online Diabetes Support Team” (ODST) was launched in 2003 on Christmas Eve, with three moderators to read through questions and forward them to the 10 people who had signed on as “responders.”
ODST very quickly outgrew the Excel spreadsheets that were originally used to keep track of its operations. Today, ODST receives 200-300 requests a month – 40 percent of them relating to diagnoses within the past year. Earlier this year, the program celebrated a huge milestone when it received its 20,000th question.
Today, there are 10 moderators – including Steve and Ardy – and at any given time, up to 100 responders, one of whom is Steve’s daughter, Allie, now 24.
“I never imagined it would grow like this; I really never did,” Steve says. “It’s really pretty cool. It was all done totally grassroots, all by the seat of our pants, at no cost to JDRF.”
The “one-to-one targeted connection” is what makes ODST particularly special, Steve says. Moderators try to forward each question to a responder who has experience with the issue being described. For example, if a teen wants advice about the best way to keep an insulin pump hidden under her prom dress, the moderator will identify a responder who has tackled that herself. If a mother is concerned that type 1 diabetes will keep her son from being able to play soccer, the moderator seeks a responder who has been there, too.
The site gives no medical or legal advice. Rather, ODST is “just people whose lives have been impacted by type 1, giving advice about day-to-day living with type 1 diabetes,” Steve says.
The ultimate goal is to hook questioners up to their local chapters – so that they can then connect with other type 1 families in their communities and also with other JDRF programs that can help them live well with type 1 diabetes.
Beyond helping people, ODST has also had a big impact on JDRF as an organization, Steve says. “We now see outreach as part of what we should be doing,” he says. “ODST has helped change the culture of JDRF.”
sTeVe WINeRConnecting for a Cause: The story of ODsT
dO
nO
r s
up
pO
rT
i
Jdr
F
Bonnie and Lawrence Kivel
Tony and Sheryl Klein
Mr. Maury Klumok
The Koch Foundation
Steve and Marilyn Kraft
Katherine Kupferer
Latham & Watkins, LLP
Judy and T. Scott Leisher
Christopher and Rebecca Lien
The Lincoln Electric Company
Donna Longo
Gloria Loring via Are You Smarter Productions, Inc.
Shelley and Douglas Lowenstein
Edward and Kathy Ludwig
Lynyrd Skynrd
Macy’s Foundation
Major League Baseball Players Alumni
Al and Claude Mann
Linda and Aaron Martenson
Uzal and C. Jun Martz
Marvin L. Baker Family Foundation
Mashantucket Pequot Tribal Nation
Susan and James Maslowski, Sr.
Stuart and Flora Mason
Estate of Earl V. Mason In the Name of Alice E. Mason
Maxon Precision Motors, Inc.
Mazda North American Operations
Sarah and Bryan Mazlish
The H.F. McCarty, Jr. Family Foundation
Mr. and Mrs. James McDonald
McKesson Foundation, Inc.
McKinney-Geib Foundation
Kim Medley
Menasha Foundation
Mesirow Financial
Stanley Meyers
Ron and Diane Miller
Mr. and Mrs. Eugene C. Miller, III
Millstadt Optimist Club
Beth and J. Barry Mitchell
Estate of Marian L. Moore
Morgan Stanley
Mother Tried Foundation
Motorcar Parts of America (MPA)
Leslie Mulholland
Mure & Carone P.C.
Harvey E. Najim Family Foundation
James & Sally Nation Foundation
Barbara and Thomas Neal
The Neilsen Company
Daryl and David Nelms
New Hanover Regional Medical Center
NJ-Sim Foundation, Inc.
Norjana Charitable Foundation
Old World Industries
Omaha Steaks
O’Neal Steel
Optima Fund Management, LLC
Mike and Trina Overlock
Dr. Graydon and Shelley Page
Palmetto Restaurant Group, LLC
Norma Parker
John J. and Joan M. Pasteris
Loretta and Douglas Patterson
John and Cindy Paul
Pavarini McGovern, LLC
PCB Piezotronics
peermusic
Penn Traffic Company
PepsiCo
Perot Foundation
Marilyn and Phil Perricone
Robert and Jill Petcove
Jeff Petro
Peyton Manning Children’s Hospital at St. Vincent
Piccadilly Restaurants
PIMCO Foundation
Roy and Yvonne Polatchek
Melinda and Richard Poulton
The Price Family Foundation, Inc.
PricewaterhouseCoopers
Publicis
Mitchell and Nina Quaranta
Stephen and Anne Rader
Ron and Barbara Rapaport
Gary and Anita Rathburn
Chris and Sarah Redlich
Mr. and Mrs. Jack Reed, Jr.
Reed Smith, LLP
Melissa and Thomas Reedy
Mr. John Reisman
Mr. and Mrs. Robert and Bobbi Reitzes
REMY
Donald and Nancy Resnick
Michael and Joannie Rich
Mrs. Debby Robbins
Robert W. Johnson, IV Charitable Trust
Robindale Energy Services, Inc.
C.H. Robinson
Linda Benge and Paul Robshaw
Lisenne Rockefeller
Julie and Len Rodman
Kathy and William Roe
James and Sharon Rohr
Mr. and Mrs. Scott C. Rolles
The Ron Santo Golf Experience
Kim and David Roosevelt
Harriet Ross
Toby and Michael Rozen
Saipem America
Jack and Anita Saltz Foundation
Sanofi-Aventis
Thomas and Mary Pat Santel
Margaret and Robert Schafer
Estate of Amelia Schmitz
Jennifer Schneider and Dain DeGroff
Shakopee Mdewakanton Sioux Community
Alan and Sandra Silvestri
Ms. Sydney Simons
Arnold J. Simonsen Foundation
K.P. Singh
Smoker Friendly International, LLC
Sony Electronics, Inc.
Estate of Margaret Sorensen
Mr. and Mrs. Joseph Spano
Starcom MediaVest Group
STERIS Corporation
Susan and Rick Sterling
Barry and Mimi Sternlicht
Carol Stillwell, Stillwell-Hansen, Inc.
Sun Products
Kris and Greg Swetnam
Tata Consultancy Services
Telvent DTN
The Thomas Foundation
Joan and Byron Thompson
Sharlyn and Wade Threadgill
Title Guaranty of Hawaii
Touchstone Communities
Tower Loan
Trozzolo Communications Group
TRICO
University of California
UPS
29
www.jdrf.org/diabetessupport
Jdr
F i dO
nO
r s
up
pO
rT
JDRF’s Online Diabetes Support Team has handled more than 20,000
requests from people with a type 1 diabetes
connection seeking support.
RES
EAR
CH RESOURCES RESULTS
30
MaJOr dOnOrs & parTners continued
Valero Energy Foundation
Bruce Vaughan
Vistakon, a Johnson & Johnson Company
Wachovia
Wachtell, Lipton, Rozen & Katz
The Walbridge Fund, LTD
Walmart Foundation
Teresa and Thomas Walsh
Jim and Stacey Weddle
Weil, Gotshal & Manages, LLP
Gail and Charles Welliver
WellMed
Western Refining Co.
Fred and Elizabeth Wiese
Willbros
Robin Williams
Dr. and Mrs. Byron Williams
Timothy and Christi Windler and Family
Richard S. Worthington
Workers Compensation Fund
Worth Harley-Davidson North, Inc.
Sharon and David Wright, III
Ellen and Stavely Wright
Monica and Robert Yolles
Robert and Leslie Zemeckis
$10,000 - $24,999Anonymous (16)
1st Bank
432 Park South Realty Co.
ABB Foundation
Karen Abbruzzese
Dr. and Mrs. Marshall Abes
Lisa and Michael Absatz
Absolute Pharmacy, Inc./Avalon Foodservice, Inc.
Jeff and Wendy Adams
Mr. and Mrs. John S. Adams, Jr.
AE Petsche Company
Aegon Transamerica Foundation
AEP
Aetna Foundation
AFLAC
Vikram Agrawal
Ms. Jane Aklestad
Akron Children’s Hospital
Alabama Power Foundation, Inc.
Alberto Culver
Jenna Alexander
All Access Apparel, Inc.
Allegacy Federal Credit Union
Allegheny Technologies
Jon and Mary Beth Allegretti
The Allergan Foundation
Allergan, Inc.
The Allstate Foundation
Dean and Shelby Alms
Alro Steel Foundation, Inc.
Alston + Bird, LLP
AMCI Capitol
Amedisys
American Airlines
American Express Charitable Fund
American Express Travel Related Services
American General Life and Accident Insurance Company
Ametek
Amherst Securities Group
Jenny and Gil Amoroso
Mary and Tom Anderson
Mrs. Carleen Andrews
Christine and John Andrie
Angel MedFlight
Animas
Julie Ann and Brian Annulis
Robin and Darrin Antrim
Appel Open for JDRF
Mr. Bernard Aptaker
Allen and Helene Apter
Milton Arbitrage Partners, LLC
Arch Capital Services
Archon Corporation
Arkansas Blue Cross and Blue Shield
Lisa and Jeffrey Aronin
Annabel Galva-Arthur and Jason Arthur
Dr. and Mrs. Todd Asarch
Ascent Media Group, LLC
John and Rosalind Ashkar
ASICS
Associated Packaging, Inc.
Aultman Hospital
Rick Austin
AVID
AVM
BAE Systems
BAE Systems Norfolk Ship Repair
Baggett Transportation Co.
Mr. and Mrs. Robert Bailey
Robert W. Baird
Baker Tilly
Jennifer and Don Baldridge
Susan and Jim Baldwin
Bank of America/Merill Lynch
BankPlus
Bantle & Walker
Baptist Health South Florida
Dr. and Mrs. Michael Barber
C.R. Bard Foundation, Inc.
John Bardis
Barnes Charitable Foundation
Earlene and Bob Barnes
Barona Band of Mission Indians
Irving Barr
Robert A.J. Barry
Jennifer and John Basham
Richard Bassuk
Coca Cola Bottling of Baton Rouge
Patrick Baumgarten
Baylor University Medical Center
BBVA Compass Bank
BD Medical
Edwin Beachler
Jennifer and John Beard
Elizabeth Ann Beck Foundation
The John and Frances Beck Family Foundation
Becker Family Foundation
Robert and Kellie Belk
Dr. William F. Bell
Bender Foundation
Brian Benjet and Kim Emmons-Benjet
Mignon and Les Bentley
Brent Berge
Berkeley College
W R Berkley Corporation Charitable Foundation
James and Diane Berliner
Robert and June Berliner
Bernstein Management Corp. (Joshua Bernstein)
Ray Berry
Tom and Lise Bessant
Susan and Stan Bever
Mr. and Mrs. Tom Bibb
Bingham McCutchen
W. Bisso, IV
Black, Starr & Frost
Greg Blackmon
Mr. and Mrs. Thomas Blackmon
dO
nO
r s
up
pO
rT
i
Jdr
F
Every year, more than 30,000
new cases of type 1 diabetes
are diagnosed in children and
adults.
RESEARCH RESOURCES
RES
ULT
S
Frank and Sandra Blanchfield
Mr. and Mrs. Gary Has
The Bill Blass Foundation
Marv and Toby Blecker
Joann Blehi
Bloomberg Financial
Bloomington Lions
Blue Bird Auxilliary
Blue Cross Blue Shield of Alabama
Blue Cross Blue Shield of Arizona
Blue Cross Blue Shield of New Mexico
Blue Cross Blue Shield of North Carolina
Blue Shield of California
Blue Slate Solutions, LLC
Blue Package Delivery
BNY Mellon
The Boeing Company
Mr. and Mrs. Michael and Stacey Bonagura
Judy Bond
Bonner Family Private Foundation, Inc.
Shannon and Rik Bonness
Daniel and Deborah Booker
Borger Management
Boston Scientific Corporation
Mr. and Mrs. Grant Boyd
BP Activities Association
Elizabeth and Charles Bracken
Dan and Annette Bradbury
Judy and Ray Brandt
Brasfield & Gorrie
David and Gail Braswell
Cheryl and Bob Brecht
Brencourt Advisors, LLC
Mr. and Mrs. Gregory Brenneman
Warren and Elaine Breslow
Mr. and Mrs. Tracy Brettmann
Anastasia and Nicholas Brien
Mr. and Mrs. Chris Broders
Greg Brody
Bill and Betty Brooks
Brooks Sports, Inc.
Brothers Air & Plumbing
Mr. and Mrs. Bob Brown
Brown & Tarantino
Tammy and Bruce Broyles
Brubaker Family Foundation
Bruce Bergman Foundation
Mary Lou and Stewart Bruce
Mr. and Mrs. Mike Bruns
Ms. Kirsten Buchanan
Bucyrus Foundation
Gary and Loraine Budke
The Bugas Fund
Bulgari Corporation of America
Mary Elizabeth and Jeffrey Bunzel
David and Barbara Burstin
Burstin, Burstin & Frantz
Business Support Group For Platt College
C.W. Butler
Lynn and Chad Buxton
Byrne Family Foundation
C.H. Guenther & Son, Inc.
Cablevision Systems Corp.
Cactus Software
Becky Cage
Steve Cage
Gloria and Louis Cairo
Cajun Cruisers
Jo Ann and Peter Calvanico
The Capital Group Companies Charitable Foundation
Karen and Peter Capuciati
Car Program, LLC
Cardinal Health
Cardone
Alexis and Scott Carmer
Caroselli, Beachler, McTiernan & Conboy
The Carriero Family
Evelyn C. Carter Foundation, Corp.
Suzanne and Michael Carusillo
The Thomas and Agnes Carvel Foundation
Mary Kate and Rob Cary
Karen and James Case
Casey’s Charities, Inc.
Mr. and Mrs. Andrew Cash
Mr. and Mrs. Jerry Cash
Catholic Archdiocese of New Orleans
Catholic Healthcare West
Mike Cavallo
CB Richard Ellis
The Cementworks, LLC
Centennial Bank
CenterPoint Energy
Centre Partners
Chadbourne & Parke, LLC
Champagne
Llee and Jill Chapman
Chapman Family Foundation
Charter Business
Chevron Products Company
Chevron Oak Point
City of Chicago
Chicago Cubs
Chicago Title Insurance Company
Children’s Hospital of Los Angeles
Children’s Hospital of Pittsburgh of UPMC
The Children’s Regional Hospital at Cooper
Mrs. Celeste F. Childs
Richard and Barb Christensen
Dianne Christensen
Chubb & Son Incorporated
Citigroup, Inc.
City National Bank
Toni and Tim Clark
Classic Industries, Inc.
Mrs. Mary Clay
Clean Energy
Clear Channel Communications, Inc.
The Clingen Foundation
Martin Cobb
The Coca-Cola Company
Mr. and Mrs. Fielding Cocke
Ron and Susie Codd
Coffee Serv
Neil and Marcy Cohen
Sandra and Sheldon Cohen
Rhonda and Russell Cohen
Lisa and Gary Coleman
Steve Collins and Carmen Gantt
Joe and Laura Colmery
Comcast
Community Hospital of the Monterey Peninsula
Community Foundation of North Texas
Community Foundation of Tampa Bay
Community Surgical Supply
Stephen Conley
Stephanie and John Connaughton
Marsha and Michael Connellan
Lisa and Ken Conway
Todd and Beth Cook
Mr. Richard Cooper
Cops Running for Charity
31
Jdr
F i dO
nO
r s
up
pO
rT
www.jdrf.org/adults
JDRF’s Adult Type 1 Toolkit
has been downloaded by
nearly 4,000 people.
RES
EAR
CH RESOURCES RESULTS
Cordray Foundation
Corn Products Specialty Ingredients
Missy and Chris Costello
Covance
Coventry Health Care
Faye L. and William L. Cowden Charitable Foundation
Amy Coyer
Carol and Denis Crawford
Creditors Collection Service
Lynne and Richard Creed
John and Karen Creelman
Kitty and Tom Crisham
CTS Corporation
Dr. Vincent and Mrs. Cheryl Culotta
Debbie and Guy Culpepper
CUNA Mutual Group
Joanne and Fred Cunha
Alice and Craig Cuvelier
Elinor M. Cuvelier Trust
Cy Pres Class Action Settlement
Daedalus Foundation
Lauren Daitch
Stacey and Don Dale
John and Georgia DallePezze
Dr. William H. Danforth
Dr. and Mrs. Howard Darvin
Data-Mail, Inc.
David Winans GMAC Real Estate
Mark and Nancy Davis
DaVita
Dayco Corporation
The Dayton Foundation
Dean Health Plan
Michael Dearing
Dr. and Mrs. William Deaton
Thomas and Lorraine Deeney
Elizabeth and Seth Deleery
Dell, Inc.
Delta Dental Plan
Deltic Timber Corporation
Dematic Corp.
Estate of Paul Deniger
Desert Diamond Casino
Leanne DeShong and James Conlon
Michael DeSimone and Dr. Susan Hughes
Steve and Nanette DeTurk
Mr. and Mrs. Richard DeVos
DexCom, Inc.
Diamond Management & Technology Consultants, Inc.
Dick’s Sporting Goods
Louis DiNardo and Julie Stein
Dawn and Sid Dinsdale
Mr. and Mrs. Kane Ditto
Estate of Richard Nason Doheny
Donatelle Plastics
Estate of John and Mary Donecker
Doner Advertising
Barbara Donnell and Scott Markus
Donovan Wright Advisors, LLC
Dopkins & Co.
Yale and Sherrie Dorfman
Rans and Margaret Douglas
Douglas J. Aveda Institute
Dove Family Foundation
Downey & Company
Diana and Robert Doyle
Dreisenszun Family Foundation
Mr. and Mrs. James Drone
Bill and Barb Drotar
Drury Inns, Inc.
Lee Ducat
Dunkin Donuts
Duplicolor Products Company, Inc.
Eunice L. Dwan 1991 Irrevocable Trust
Pat and John Dyer
Christopher and Bijen Dyrek
Eagle Materials, Inc.
Mr. and Mrs. Jay Eastman
Mr. and Mrs. John Eastman
Ms. Louise Eastman-Loening
Pete and Martha Eckerline
Edgepark Medical Supplies
Mrs. Franklin S. Edmonds
Pamela F. and Franklin S. Edmonds, Jr.
Edsal Manufacturing Co., Inc.
Education Management Corporation
Lia and Herm Edwards
Carl Edwards Motorsports
Debbie and Richard Egan/Debbie’s Dream
John and Ginger Eichhorn
James Ellis and Margaret Brady
Gary and Cindy Ellis
Dennis and Bonnie Ellman
Elvis Presley® Charitable Foundation
Emerald Cascade Restaurant
Emkay, Inc.
Mike and Sharon Ensign
Epic Systems Corporation
Pete and Wendy Ernaut
Ernst & Young
Annette S. Eskind and the Eskind Family Foundation
Es-O-En Dba Taco Bell
ESPN
David Ettinger M.D., D.M.D. and Jacqueline Ettinger
ExxonMobil
Marcia and Joel Faber
Mr. and Mrs. Brian and Robyn Fagen
Lindy and John Fain, OD
Families for a Cure
Bronwyn and Scott Farber
Farmington Bank
Federated Clover Investment Advisors
Federated Kaufman Fund Utsch, Hans
Kelly and Carl Fellbaum
Fenco
Bill and Kristin Fenech
Whitney and Peter Ferré
Fight for Children
Financial Concepts, Inc.
Karey and Michael Finch
Mr. Marvin Finkelstein
Caryn and Douglas Firebaugh Foundation
First Commonwealth
FiServ
Scott and Betsy Fishbone
Shelly and Scott Fisher
Tammy and Steve Fitzgerald
Ken and Jane Fitzsimmons
Joseph A. Fleck
Susan and Kevin Flynn
Focus Express Mail Pharmacy
Janet and Ken Follansbee
Fort Pitt Capital Group
Foster Parts
Daveen and Alan Fox
Melanie and Jeff Fox
FPD Brakes
Mr. John Robert Franke
Frankel Family Foundation
Sheri Frazier-Kesner
32
MaJOr dOnOrs & parTners continuedd
On
Or
su
pp
Or
T i
Jd
rF
RESEARCH RESOURCES
RES
ULT
S
Roughly half a million people in 230
cities nationwide participated in the
FY2010 Walk to Cure Diabetes.
33
“I try not to let diabetes affect what I want to do,” Mary says. “I’m not inhibited by it.”
In fact, the Lucases have created ways to remain proactive, productive, and positive in the face of the disease’s challenges. Parents Sarah and Don Lucas are the founders of Spring Fling – an annual fundraising event for JDRF’s Greater Bay Area Chapter that includes a golf tournament, a ladies luncheon and boutique, and a themed evening bash. Sarah now sits on the chapter’s Board, serving as Vice President of Special Events. Don, a venture capitalist who served on JDRF’s Silicon Valley Branch Board for six years, is a founding investor and Board member of Dexcom, one of the companies that provides continuous glucose monitors for research being funded by JDRF’s Artificial Pancreas Project.
Their involvement with type 1 diabetes began in November 1998, when the family was on the brink of another “next big thing.” With three children in tow, the Lucases were staying with friends for a couple of days while moving into a new home. When Mary, then seven, became very
ill, they rushed her to the hospital, where she was diagnosed with type 1, a disease the family knew little about at the time.
The Lucases were determined to keep life as normal and active as possible. As soon as they were settled into their new home, Sarah – already an avid charitable event planner – rented out a bowling alley, set out a donation box, and invited their friends to come out and play to support type 1 diabetes research. While researching organizations to send the proceeds to, she discovered JDRF.
The next year, when their bowling event brought in $40,000 for JDRF, the Lucases got a call from the Greater Bay Area Chapter’s executive director, who called their grassroots efforts impressive and asked if they would be interested in creating an annual chapter event. Sarah and Don agreed, and came up with the idea for Spring Fling. It began with inviting friends and colleagues to participate, and has grown into a multi-event community tradition that has raised nearly $5 million for JDRF. The 10th-anniversary Spring Fling is set for April 1, 2011, and the honorary committee – which celebrates those who have helped make it so successful year
after year – has a fundraising goal of $1 million.
Throughout its years of growth, Spring Fling has remained family-and-friends-oriented, much like the Lucases themselves, which makes them proud. Each year, the entire Lucas family is involved in planning and running Spring Fling, including Mary and her siblings, Jack (16), Kate (12), and Henry (10). Explains Sarah, “It’s marked on the family calendar each year much like a holiday…it’s part of the fabric of our lives. From now until there’s a cure, I see our family continuing this event.”
Sarah hopes her family’s story underscores the message that everyone can make a difference. “The point is to do something,” Sarah urges. “That’s what we try to model for our kids. That’s our message. But also have fun while you’re doing it.”
And it’s just this mantra, “do something,” that keeps the family positive and productive. It’s why Mary’s type 1 diabetes is an important detail in her life, but not its definition. Her life is hers to design, with all of her “next big things.”
At 18, an ambitious and enthusiastic Mary Lucas is on the brink of her “next big thing”: planning her move from Atherton, CA to New York City to study fashion design at Parsons, her dream since she was in grade school and making dresses out of fabric remnants. Being on the brink of the “next big thing” is a common theme for the entire Lucas family, and their vigorous approach to life is reflected in how Mary has managed her type 1 diabetes.
TurningChallenge
into possibilityLuCAs familyJd
rF i d
On
Or
su
pp
Or
T
34
MaJOr dOnOrs & parTners continued
Fred Meyer Stores
The Robert Freeman Ford Foundation
Fried, Frank, Harris, Shriver & Jacobson, LLP
Robert and Lori Frieling
Fringe Benefit Life Insurance
Frito-Lay
Fry Communications, Inc.
Michael and Elizabeth Gallagher
Lori and Greg Gallant
John and Lori Galley
Robert R. Galvin
Janie and Michael Gantt
Emma and Mark Garrett
Steven J. Gartner
Mr. and Mrs. Oscar Garza
Kim Gatlin
GBS Corporation
GE Asset Management
GE Capital
GE Foundation
Mary and James L. Geisman
Gene & Jerry Jones Family Charities
James and Janice George
Drs. David and Katie Gesensway
Gibbons P.C.
Gibson, Dunn & Crutcher, LLP
Gidick Family Trust
Gilbane Building Company
Cliff Gilbert-Lurie
Mike and Susan Gillfillan
James Gleason
Mark and Sue Gleason
Mark and Hanna Gleiberman
Globallogic, Inc.
Gohmann Asphalt/Construction, Inc.
Janie and Brian Gold
Goldman, Sachs & Co.
Charles and Rhonnie Goldstein
Jennifer and Alan Goldstein/Team Alaina
Daniel and Margo Good
Good Family Foundation
Janet Goodman
Ms. Diana Goodrich
The Goodyear Tire and Rubber Company
Andrew and Amy Gordon
Brenda and Robert Gordon
Mr. and Mrs. Keith and Wendy Gordon
Michael and Loren Gordon
Gabriela and Peter Gottlieb, M.D.
Joseph Grady
Steve Graham
Greater Houston Community Foundation
Edith Dee Green Foundation
Greenacre Properties
Jonathan and Stefanie Greenberg
Greenberg Glusker Fields Claman & Machtinger, LLP
Estate of Dorothy Greenfield
Debra and Bruce Grewcock
GRI Engineering & Development
Grillsmith Restaurants
Mr. Paul and Dr. Donna Roy Grogan
Estate of Abraham Gross
Group Health
Andy and Julie Gruber
Mrs. Bridget M. Guerin
Guess? Foundation
Christian and Cathy Haase
Hagans, Bob & Burdine
William Hake
Mrs. Sally Halff
Halliburton
Harry and Lynne Hallowell
Mr. and Mrs. Walter Halverstein
Clay Hammerstein
Hanify & King, P.C.
Carl and Val Hansen
The Mark and Anne Hansen Foundation
Harbert Management Corporation
Eric and Deidre Harger
Julia and Jeremy Harman
Jim and Janet Harris
Jennifer and John Hart
Mr. Kevin Harvey
Stan Hastings
Haugo Bancshares, Inc.
Joy and Ralph Hauser
Desmond and Jen Havilcek
Jeff and Christina Hawkins
Mr. Victor Haydel
Hilda Laura V. Haynes Family Foundation – Melissa M. Amice Haynes
Healthways
Dan and Carolyn Heard
The Helen G. Hauben Foundation
Julie and Michael Hellmers
Patricia and Gary Henn
Bruce Herring
Hershey Entertainment & Resorts
Hess Foundation, Inc.
Hewitt Associates
Heymann & Fletcher Esqs.
Jewel and Mark Hickman
Hickory Printing Solutions, Inc.
David and Dawn Hickton
Mr. and Mrs. John Hipp
HITT Contracting, Inc.
Hoag Memorial Hospital Presbyterian
Michael and Jennifer Hobbs
Mason Hoffman and Family
Mr. and Mrs. Thomas Hoffman, Jr.
Holiday Management Foundation, Inc.
Brad and Deb Hollinger
Emily and Steve Hollis
The Holzman Family Foundation
Home Box Office, Inc.
Chiu Has Hong
Russell Hoppenstein
Horne Brothers Construction, Inc.
Lorraine and Graeme Houston
Mrs. Helen M. Howard
Mr. and Mrs. Billy Howard
Howrey, LLP
HAS Commercial Real Estate
Janna Hubble
Jeff and Catherine Huge
Clayton and Gina Hughes
Greg Hughes
Joe and Marilyn Hughey
Roy A. Hunt Foundation
John Iberle
IBM Employee Services
ICT Group, Inc.
Estate of Mary E. Ide
Illinois Tool Works, Inc.
Frank Ingrassia and Elizabeth McCaul
Inserra Supermarkets
Interactive Concept Management, LTD.
Interdynamics, Inc.
International Bank of Commerce
Interpublic Group
Intuit
Ion Media Networks
International Paper Foundation
dO
nO
r s
up
pO
rT
i
Jdr
F
In FY2010 Team JDRF was
launched to support people in holding their own
fundraisers for JDRF.
RESEARCH RESOURCES
RES
ULT
S
Chris and Tonia Irion
Iroquis Avenue Foundation
Cindy and Jim Irvine
ITT Night Vision
Allen Ivester
J & J Family Foundation
The J.E. and Mildred Waggoner Family Foundation
J. Lawrence Khakis of Carmel
JP Morgan
Jabil Circuit
Darren and Terry Jackson
Katie and Steve Jackson
Jackson Family Wines
Arlene Jacobs, M.D. and Allen Feltman
Brandon and Kim Jacobs
Hal and Debby Jacobs
Irwin and Joan Jacobs
Jeff and Deni Jacobs
Paul and Stacy Jacobs
The James Family Foundation
Sean and Jennifer Jeffries
Cathy and Peter Jensen
Dr. and Mrs. E. Forrest Jessee, Jr.
Jig-A-Loo
Joe and Ora Vella
GE Johnson Construction Company
Greg and Tracy Johnson
The James Hervey Johnson Charitable Trust
Jay Johnson and Hannah Tenneson
Mrs. Jennifer U. Johnson
Jim and Laura Johnson
Ron and Karen Johnson
Rupert and Maryellie Johnson
Jones Lang LaSalle
Estate of John W. Jordan
John and Andrea Jordan
Josco
Catherine and Thomas Joyce
Sarah and Ron Jury
Chara Schreyer & Kadima Foundation
Bob and Marissa Kagle
Robert J. Kahn Foundation
Craig and Rose Kaintz
Jackie and Norm Kallan
Kansas City Chiefs Ambassadors Charitable Foundation
Kansas City Power & Light District
35
From heartbroken to heroic: A story of generous high-Achievers Mackin Family
When Larry and Suzanne Mackin’s daughter, Ali, began rapidly losing weight and feeling weak at age 14, they took her to the doctor, hoping that the problem could be easily fixed with a little nutritional guidance. But to their horrific surprise, tests showed Ali’s blood sugar was at 500, and she was rushed to the hospital. Type 1 diabetes had entered the Mackins’ world, and they knew life would never be the same.
Since that day, Larry and Suzanne have thrown themselves wholeheartedly into volunteering with and supporting JDRF to work for better treatments and a cure for Ali and everyone with type 1 diabetes. And even though Ali is now an adult – a recently married 26-year-old who works in the family business and is setting up her new home – Larry and Suzanne remain devoted to JDRF. As Suzanne says, “I don’t like to do anything halfway; I feel like I have to stick with things and carry them through fully.”
The Mackins’ contributions to their Oregon/Southwest Washington Chapter have been – and still are – extensive. Larry has served as a Board member for more than six years and was Board president for two. Larry and Suzanne have also been Gala co-chairs for five years and are major contributors to and catalysts of the event’s success. In fact, they are ongoing Gala sponsors and have donated auction items, given to Fund A Cure, and even provided transportation for auction items and other chapter donations. For a five-year stint, they were the Gala’s “Presenting Sponsors,” helping to ensure its success with a generous contribution of $20,000 a year. The family also holds JDRF fundraising events, including poker and golf tournaments. The Mackins have even enlisted their company – Mackin’s Auto Body – to become a Walk sponsor, form a Walk team, and sell Sneakers in its six locations. In recognition of all that they do, Larry and Suzanne were honored at the chapter’s 2002 Gala. Says Larry, “Every day, we try to make a difference with diabetes; it’s our passion.”
Carol and Edward Kaplan
Leon and Mary Ellen Kaplan
Kevin and Janet Katari
Katherine Herman Charitable Remainder Trust
Ira J. Kaufman Family Foundation
Jack Kay
KBR
Tonya and Michael Keith
Joan and Herb Kelleher Charitable Foundation
The Kelleher Corporation
Keller Family Foundation
Mr. and Mrs. Richard Kellner
Kemps
Kenan Advantage Group
Ken Kendrick
Margaret L. Kenyon Trust
Terri and Michael Kerber
Carla and Michael Kilbane
Mr. and Mrs. David Kim
Kingston Technology
The Kinney Family
Estate of Julia J. Klapec
Stephen Klar and Janice Gross
Kristin and Jim Klint
Mr. and Mrs. Todd Klumok
Knights of Pythias Diabetes Research Association
Mrs. Stephanie Knippel
Dr. John Knoedler
Knollwood Adopt a Charity Association
Katchen and Mark Knorringa
Tracy and Mike Koeppen
Mark Kogan
Jdr
F i dO
nO
r s
up
pO
rT
36
dO
nO
r s
up
pO
rT
i
Jdr
FMaJOr dOnOrs & parTners continued
when Jared Allen was a rookie for the National Football League’s Kansas City Chiefs in 2004, his roommate
received a Walk to Cure Diabetes fundraising letter from a friend’s son. Jared read it and was moved by the child’s description of the challenges of type 1 diabetes. It inspired him to pick up the phone.
“I was looking for something to get involved with,” he says. He talked first with the child’s father about living with diabetes and then with JDRF’s Yvonne Miller about how he might be able to help. He agreed to appear at a Walk awards dinner for the Kansas City Chapter – a first step that has evolved into a marathon relationship.
Today, Jared describes his many contributions to JDRF in a typically understated way: “I got involved with some kids, and it’s gradually grown over the years.” Yet that doesn’t begin to adequately describe what he’s done, especially for the Kansas City Chapter: appearing at the Dream Gala, initiating a “Sack Diabetes” fundraising program, serving as the Walk
Celebrity Chair, and representing JDRF at a variety of community fundraising events. On the national level, Jared appeared at Children’s Congress in 2009, offering support and inspiration to children with type 1 from across the nation.
Miller credits Jared’s involvement with boosting JDRF fundraising by more than $300,000, and she says his partnership has given the chapter an entrée into the entire Chiefs organization.
“Our relationship with Jared has evolved into so much more than him serving as our Celebrity Chair...he has gone from interested advocate to evangelist,” Miller says. “He truly has become part of the Kansas City Chapter family. He has visited kids in the hospital, gone to their baseball games, basketball games, high school football games, swim meets, and school plays.”
One of the most striking things about Jared’s involvement with JDRF is the fact that he has no direct experience with type 1 diabetes. “I knew the kids were great,” he says of his decision to become involved. “Just hanging around with the kids grew my relationships with the families, and I learned more and more about diabetes.”
In 2008, Jared joined the Minnesota Vikings, his talents rewarded with what at the time was the most lucrative contract ever for a defensive player. Since then, he has also become supportive of JDRF’s MinnDakotas Chapter, appearing in public service announcements, among other initiatives. Jared has also started his own charity, building homes for wounded war veterans. Still, he remains dedicated to JDRF.
One of the things that inspires him is JDRF’s results-oriented research. He has learned a lot about the search for a cure and understands the challenges involved. “It’s one of those things where on the research side, every step is one step closer, but I know these kids would like to see the complete cure altogether.” he says.
What keeps him committed are the kids and families he’s met.
“Big corporate events, sponsorships, and fundraising are all part of what you’ve got to do,” he says, “but it’s always good to hang out with the kids and families, see their struggles firsthand, and get to know them…I don’t even think of it as charity; I’m just hanging out with friends now.”
For Jared, the visibility he can bring to type 1 diabetes is secondary to what he brings to these families. “I think the
biggest thing…is the time I’ve spent with families,” he says. “Even if it’s just an hour to take the kids’ minds off the disease that they’re battling every day, that’s the greatest gift I can give them.”
JAReD ALLeN
One of the most striking things about Jared’s involvement with JDRF is the fact that he has no direct experience with type 1 diabetes.
Just Because he Cares: Jared Allen’s Inspiring Commitment
37
Seth Kogan
Florence and Chester Kolczewski
Darla and Jerry Kollar
KPMG
Kraco Enterprises, LLC
Harvey and Minna Kramer
Steven and Cindy Kramer
Carolyn and Morris Kremen
Ure and Dianne Kretowicz
Estate of Ruth M. Kroon
Mr. Michael Krupka and Dr. Anne Kubik
Mr. and Mrs. Frank Kudla
Laffey McHugh Foundation
Mr. Marshall Laitsch and Ms. Carolyn Powell
Lamar Bruni Vergara Trust
Estate of Gilbert E. Lamothe
Land O’Frost
Jim and Maggie Lang
Lannan Foundation
Las Patronas
The Lawton Family Fund
Mary and Jack Leary
Joann Leatherby and Dr. Greg Bates
Mr. and Mrs. Franc Lee
Leerink Swann & Co.
Matthew and Violet Lehrer
David Lewis
Geoffrey and Karen Lewis
Rick and Lisa Lewis
Lewis-Sebring Family Foundation
Elizabeth Liebman
Liner, Yankelevitz, Sunshine & Regenstreif, LLP
Joe and Debbie Lippincott/Lippincott & Lippincott
Robert and Elizabeth Lisowski
Little Feet and More, Inc.
Local Edge
Jacinta and Robert Loewen
Long Island Diabetes Support Foundation, Inc.
Lormar Foundation
James Lott
Estate of Barbara Louis
Louis Yager Cantwell Private Foundation
Louisiana CNI, LLC
Louisiana Machinery
Lowdon Family Foundation
Mr. and Mrs. Steve Lowit
Jacqueline and Richard Loynd
Lozier Foundation
Cheryl and Tom Lozowski
Forrest and Charlotte Lucas
The Lucas Family
Lucas Oil Products
Larry L. Luing Family Foundation
Kimberly Lund
Kristina and Marvin Lustiger
Richard Lutz
M & H Building Specialties, Inc.
M.D. Anderson Foundation
Mr. and Mrs. James MacDonald
Will MacKenzie
Mackin’s Auto Body
Macquarie Group Foundation
MacroGenics, Inc.
Heather and Jim Madden
Joe and Wendy Madden
Madison Square Garden
Jerome and Frances Magner
William Mahoney
Major League Baseball
Robin and Charles Malk
Mr. and Mrs. Hampton Mallis
Mr. and Mrs. Bob E. Mallory, Jr.
Peter and Catherine Malone
Mr. and Mrs. John M. Maloney, Jr.
Amir & Rosita Manocherian Family Foundation
Marathon Oil
Mr. and Mrs. Barry Margolis
Robert Margolis
Marina Medical Billing Services
Marion W. Minton, Walter J. Minton Foundation, Inc.
Mark Lauria Associates, Inc.
Markey’s Audio Visual
John and Lisa Marquardt
Jane and Z. Marshall
Melinda and John Marshall
Kara and John Martin
Massapequa Youth Lacrosse Club
Mattel, Inc.
Barbara and Hank Mawicke
W. David and Mary Maxwell
Louis Mayberg
Mark and Anna Maynard
McAlester Radio
Mr. and Mrs. Josh McCarter
Elizabeth and Jake McCarthy
Mr. and Mrs. Ken McClure
McConnell Development
Billie and Scott McCormick
McCownGordon Construction, LLC
Mr. and Mrs. Kyle McCoy
McCutcheon Enterprises, Inc.
Mr. and Mrs. Patrick J. McFeeley, Sr.
Mr. and Mrs. Patrick McFeeley, Jr.
Sharon McGill
Eric and Donna McGovern
Andy and Dan McGuire
Virginia McGuire Foundation
Marc and Mandy McIntyre
McKamish, Inc.
Kevin McKenna
McKesson – Greenville, TX
McNeil Nutritionals
MED3000, Inc.
Medical Center of Plano
Meguiar’s, Inc.
David W. Meier, Jr.
Meijer, Inc.
Menasha Corporation
Vickie and Bob Mercer
Mercy Medical Center
Nancy and Les Meredith
Merisant US, Inc.
Merrick Ventures, LLC
Estate of Robert H. Merrill
Merrill Companies, LLC
Merrill Lynch
Metro East Annual JDRF Golf Tournament Association
Foy and Judy Meyer
Michelin
Micrmetl
Mid-Hudson Valley Federal Credit Union
Elise Mikus
Milano Foundation
Cindy and Rich Miller
Diana and Mike Miller
Lisa and David Miniat
Pauline and Ronald Miniat
May Mitchell Royal Foundation
Howard and Judy Mock
Moe’s Southwest Grill
Molton Brown
Peter and Sarah Monaco
Montgomery Coscia Greilich/ExponentHR
Jdr
F i dO
nO
r s
up
pO
rT
JDRF Ride to Cure Diabetes
participants raised an average of
$4,100 each for diabetes research
in FY2010.
RES
EAR
CH RESOURCES RESULTS
Monument Realty
Moore and Van Allen
Morgan Keegan & Company, Inc.
Morgan Stanley-Investment Banking (NYC)
Thomas Morhaus
Alan Morris and Pia Exber-Morris
Mr. and Mrs. Robert Morrison
Julie and John Morrow
Michael and Jenna Morton
Mountainstar Healthcare
Patty Mozart
MSC Industrial Direct
Douglas Mueller
Sue and William A. Munck
Munck Carter, LLP
Mr. Anthony Murphy
Mr. and Mrs. Anthony Murphy
Payson and Grant Murray
Mutual of Omaha
Diana and Michael Myers
NASCAR
Nas-Walker
National Bank of Arizona
National Basketball Association
National Championship Hunt Foundation
National Philanthropic Trust
National Postal Mail Handlers Union
Mrs. Beatrice Naumann
Nauticon Imaging Systems
Molly and Skip Naylor
Laurence and Susan Nayman
The Nancy Lurie Marks Family Foundation
Nancy Near
NeBAA
Nebraska Heart Institute
Neil and Jane Golub Foundation
Neiman Marcus
Mr. Randall Nelson
Kathi and Dirk Nelson
Meeghan and Michael Nemeroff
Nestle Waters North America
Netezza Corporation
Dave and Esparanza Neu
New York Giants
New York Media, LLC
The New York Times Company
Newbury Comics
Newmont Mining Corporation
The News Corporation Foundation
Estate of Hilda Newton
Next Chapter Associates
NIC Holding Corporation
John and Lori Niehoff
Nipro Diagnostics
Sharon and Jack Nix
Noble Corporation
Peter And Stephanie Nolan
John and Linda Nordin
Cathy Nordling
Julie and Gary Nordlund
Phyllis Nordlund
Norkus Enterprises
Daniel and Janice Norman
Normandy Real Estate Partners
Robert and Jane Norris
Jean Norris and Vincent Norton
Dellora A. and Lester J. Norris Foundation
Northern Tool and Equipment
Northern Trust
Novartis Pharmaceuticals, Inc.
Novo Nordisk Pharmaceuticals
Lance and Lou Noyes
Oakland Athletics
Estate of Hubert O’Daniels
Susan and Stacy Oelsen
Old South Home Co.
Ollila Law Group
O’Melveny & Myers
Edmond and Alice Opler Foundation
Orange Coast Magazine
Winifred & William O’Reilly Foundation
Estate of Brenda Orr
Osborn & Barr
OSMC
Osram Sylvania
Jonathan and Donna Ostrau
Bank of America In Memory of Gunnar S. Overstrom
Bill and Norma Overton
Mary Ellen and Lee Owen
Owens Illinois
PACCAR
Pacers Sports & Entertainment
Donna Pacicca and Dominic Decicco
Penny and Ruffner Page
Steve and Tamara Pann
Mark and Kathy Papermaster
Chris and Shannon Parker
Mr. and Mrs. Howard Parker
Parker Hannifin Corporation
Paul Parsons/Team Jake
Elyse and George Pasha
Varsha and Vikas Patel
The Patricia & Clarke Bailey Foundation, Inc.
Kathy and Nathan Patterson
Mr. and Mrs. John Patterson
Dr. and Mrs. Net Payne
Karin and Philip Pead
Earl Peeples, M.D.
Bob and Leslie Penkhus
Bob Penkhus Volvo Mazda VW
Drs. Jennifer and William Pennoyer
Pepper Hamilton, LLP
PepsiCo Foundation
Eric Perakslis
Perfection Hy-Test
John Peterson
Alan and Bonnie Petsche
The Pfeiffer Family Foundation
Pfizer, Inc.
The PGA TOUR / THE PLAYERS
PHH Mortgage
Philadelphia CBOA
Physicians Plus Insurance Corporation
Lynn Pieper
Vicki and Robert Pierce
Anne and Robert Pillion
Nancy and Bret Pilney
Pinnacle Bancorp, Inc.
PlainsCapital Bank
Jill Plant and James Nichols
Platte Valley Bank of Missouri
Dena and Michael Plumer
The Plymouth Rock Foundation
PNC Private Wealth Management
PNC Foundation
Dr. and Mrs. Kevin Pogreba
Patrick and Laura Pohlen
Matthew and Judith Pollack
Polo Ralph Lauren
Mr. Christopher Pongratz
Porsche Club of America Chicago Region, Inc.
Gerry Powderly and Adriana Bauza
Thomas and Tina Powderly
38
dO
nO
r s
up
pO
rT
i
Jdr
FMaJOr dOnOrs & parTners continued
www.facebook.com/myjdrf
RESEARCH RESOURCES
RES
ULT
SMore than 50,000 people follow JDRF on
Facebook.
39
David and Virginia Powell
John Powell
Prairie Meadows
Pratt & Whitney
Praxair
Linda and Richard Price
Mr. and Mrs. Lev. H. Prichard, IV
Print Shop Open
Proliance International, Inc.
Promontory Financial Group, LLC
Pro’s Ranch Market
Mr. and Mrs. Michael Provenzano
Providence Medical Group
Prudential Financial
Mr. and Mrs. John Pruitt
Pulse EFT Association
Quaero, a CSG Solution
Charles and Jeri Eckhart Queenan
Quest Diagnostics
Quicksilver Resources
Jay and Kathy Rains
Mr. and Mrs. Richard Randall
Craig Rauchle and Julie Weintraub
Raymond James Financial, Inc.
Raynbow Foundation
RB Distribution
Red Ball Oxygen
Red Rock Distributing Company
Mr. and Mrs. Ralph Reed
Kevin, Christine and Shea Reilly
Lisa and Chris Reilly
Mr. and Mrs. Ben Reitzes
The Related Companies
Remsa of America
Renée West
Don and Margie Reynolds
Reynolds American
Reznick Group
Mr. and Mrs. John Rice
Mr. and Mrs. Chris and Ginny Rich
Charles L. Richards
Richards Manufacturing/ETI
Camilla and Scott Richardson
Jim and Karin Riley
Richard and Nancy Riley
Jim Ritchie Family Foundation
Mrs. Tammy J. Ritchie
William Rittwage
RiverStone Resources, LLC
Robert J. Kahn Foundation
Anthony and Rosemary Roberto
Mitch and Jill Roberts
Peter and Leslie Robinson
Mr. and Mrs. Bud Roche
The Rockland Country Club Foundation, Inc.
Ms. Ellen Rollins
Mr. and Mrs. Gary Rollins
Ms. Nancy Rollins
Romenesko Family Dentistry
Mr. and Mrs. David Roos
Tom Roose and Joanne Thompson
Rosemary Haggar Vaughan Family Foundation
Rosler Family Foundation
Ross & Yerger Insurance, Inc.
The Arthur J. Roth Family Foundation
Marty Rumble
Mr. and Mrs. Frederick Leroy Russell, Jr.
Mrs. Doris Russell
Steve and Claudia Russell
Kerry and Timothy Ruth
RX Stat
Ryan Companies
S&D Coffee, Inc.
S.S. Medici Cosma & Damiano
Dave and Janice Sachs
Safeco Insurance
Saint Louis Children’s Hospital
Saks Fifth Avenue
Mr. and Mrs. Allen Salikof
Salt River Project
Terry Saltzberg
Sam Roosth Foundation
Samson
Samuels & Associates
San Diego Parrot Head Club, Inc.
Cary and Valerie Sandler
The Sandra Atlas Bass & Edythe & Sol G. Atlas Fund, Inc.
Sangamo BioSciences, Inc.
Estate of Mildred Sansbury
Michael and Diane Sapir
Neil and Sheryl Sarnak
Scafco Corporation
The Paul Scammell Foundation
Mr. William and Vicki Schaefer
Mr. and Mrs. Joel Schaller
Schlesinger Companies
Mark and Maria Schlossberg
Schlumberger
Ed and Donna Schmidt
Shawna and Eric Schoonveld
Mark and Jackie Shrekgast
Chris and Krista Schultz
Dr. Peter Schultz
Schulze and Burch Biscuit Co.
Peter and Kathleen Schwalje
Terri and Marc Schwartz
Mr. and Mrs. Thomas Schwartz
Scottrade
Seinfeld Family Foundation
Sellers, Richardson, Holman, West
Seneca Niagra Casino & Hotel
Thomas and Lyn Shea
Bill and Julie Sheley
Shell Oil Products United States
Mary Sheridan
John and Mary Sherman
The Sherwin-Williams Company
Jack and Sue Shilling
Shoes For Crews
John Shrewsberry and Ereca Miller
Portia Whitaker Shumaker Fund at the San Diego Foundation
Sigma-Aldrich
Mr. and Mrs. Jeff Silk
Lin and Mike Simmonds
Simmons Browder Gianeris Angelides & Barnerd, LLC
The Sidney, Milton and Leoma Simon Foundation
Mari Sinton-Martinex
Skanska USA Building, Inc.
Mike and Beth Skorich
Estate of Natalie Slesinger
Mike and Lisa Smart
Smart Pill Corp.
Ed Smith
Ellen and Lew Smith
Patty and Greg Smith
Mr. Steve Smith
Smith Family – In Memory of Jennifer Catherine Smith
Smith International
Velocity Solutions
Jeffrey and Mindy Sosland
Neil and Blanche Sosland
Southwest Securities
The Spano Family Charitable Foundation
Sperling Brothers Foundation
Jdr
F i dO
nO
r s
up
pO
rT
RES
EAR
CH RESOURCES RESULTS
Some 24 million Americans have
either type 1 or type 2 diabetes.
40
Mr. and Mrs. Joshua Speyer
Tishman Speyer
The Spiritus Gladius Foundation
Anne and Bernard Spitzer
Alana Spiwak and Sam Stolbun
Sprint
St. Louis SportsServices, LLC
STMicroelectronics, Inc.
The Julia Carell Stadler Foundation
Mr. and Mrs. Tom Standish
Robert and Connie Stanley
Staples
Stefani’s Children’s Fund
Steve and Betty Sterett
Bruce and Judith Stern
Thomas D. and Denise R. Stern Family Foundation
Mr. Mark Stevens
George and Sue Stewart
Teresa and Glen Stewart
Mr. David Stierle
John and Denise Stilley
Sting Alarm, Inc.
Stony Apparel
Storandt Pann Margolis
Stradley Ronan Stevens & Young, LLP
Strauss Foundation of Trust
Luke and Scotti Strockis
Jim and Susan Stuart, Jr.
Lee R. Stuart Family Foundation
Studley, Inc.
Heather and Tom Sturgess
Sub-Zero Foundation
Suffolk Construction Company
Dan and Katie Sullivan
Rich and Gaby Sulpizio
Summit Credit Union
Sun Capital Partners Foundation, Inc.
Sunrise Hospital and Medical Center
SuperValu
The Supreme Master Ching Hai International Association
Terese and Jeffery Surges
Susie’s Deals
Madalene and Wayne Swetnam
Scott and Tina Swisher
SXC Health Solutions, Inc.
Sysco Corporation
The Taddeo Family
Bill and Karen Talbert
Susan Talbot
Anonymous in honor of Mark Tamoshunas
Tanamera Construction
Target Corp.
Tarson Investment, LLC
The Taubman Company
Taylor International Corporation
TD Ameritrade
TD Bank
Team Zachary
Tech Group North America, Inc.
Gina Tega and Ali Partovi
James and Laurie Theiss
Telesis
John and Ethel Templeton Fund
Joni Elaine Templeton Charitable Trust
Terry World
Terumo Medical
Texas Children’s Hospital
Texas Health Resources
Mr. and Mrs. Alex Theriot
Karen and James T. Thielens
Walt Thirion
Jennifer Thoele
Mr. Ryan Thomas
Thomas E. Jernigan Foundation
Kay and Don Thorp
Jelindo and Sandee M. Tiberti
Time Warner, Inc.
Cynthia B. Tomlinson Foundation
Jan and John Totushek
Tricia and Randy Touchstone
Mr. Andy Townend
Mr. John F. Trexler
Tri City National Bank
TriMark SS Kemp
Troutman Sanders
Scott and Vonnie Trumble
Trying2help.com
Cindy and Bob Tucci and Jeff Wolfe
Rob and Gina Tuckey
Tucson Medical Center
Chris and Tracy Turner
Wayne and Susan Turner
ULLICO, Inc.
United Biosource Corporation
United Parcel Service
United States Steel Corporation
United Way of Metropolitan Chicago
Universal Lighting Technologies
Universal Weather and Aviation
University of New Mexico Hospitals
University of Pittsburgh
University of Texas Southwestern Medical Center
US Bank
U.S. Trust, Bank of America Private Wealth Management
USS-Posco Industries
Utah Del, Inc.
Valentine Capital Asset Management
Philip L. Van Every Foundation
Amy Roth and Jack Van Valkenburg
Mr. Eric Van Zwisler (Australia)
Vanderbilt University Medical Center
Vanguard Charitable Endowment Program
Variety Children’s Charity of New England
Sherrie and Anthony Varrichio
Sarah and Porter Vergon
Cliff and Jill Viner Family Foundation
ViraCor-IBT Laboratories, Inc.
Visa
Vista-Pro Automotive
Visteon Climate Control
VML Foundation
Mr. Roger F. Vorce
Vornado/Charles E. Smith
Anne Lyons and C.J. Voss
Dawn and John Vresics
W P W Foundation
W.T. Young, LLC
Judy and David Wachs
Mr. Laurence Wald
Mr. and Mrs. Richard and Edith Wald
Estates of Seymour and Gloria Wald
Milton and Miriam Waldbaum Family Foundation
The Waldman Family
Chris and Terri Walker
Estate of Lillian K. Walker
Martha and Dave Waller
Walmart
J. and J. Walsh Family Charitable Fund
Walsh and Nicholson
dO
nO
r s
up
pO
rT
i
Jdr
FMaJOr dOnOrs & parTners continued
Diabetes and its complications cost more than $174 billion a
year in the U.S.
RESEARCH RESOURCES
RES
ULT
S
hope spans generations of FamilyMonier Family
41
The Warburg Pincus Foundation
Jeanne and James Ward
The Warranty Group/TWG Holdings, Inc.
Denise and Peter Waters
Marjorie Waters
Mr. and Mrs. Robert E. Watts
Mr. and Mrs. Robert H. Watts
Missy and Chuck Wayland
Kevin and Erin Wehrenberg
James and Ellen Weil
Dr. and Mrs. E. Hunter Welles, III
Julie and Dennis Wellner
Wellpoint
Tobias and Kristin Welo
Bob and Kay Welsh
The Robert & Kathleen Welsh Foundation
The Welter Foundation
Alton and Millie Wendzel
Robin and Bradley Werner
Alice and Bruce Werstak
Bob and Gloria Werth
Wescon Construction
West Corporation
Westchester Capital Management
Western Athletic Clubs, Inc.
Jeff Westphal
Pam and Jim Whalen
Harvey and Sheryl White
Michael and Sharon White
Harvey and Annette Whittemore
Brett and Louise Wickard
Mr. Randy Wild
Wild Flavors, Inc.
Willa’s Workshop
Mr. and Mrs. A. Kelly Williams
Sarah and Daniel Williams
Williams & Connolly
Kim Williams-Paisley
Willow House
Mr. and Mrs. James Winchester
Patricia and Steven Winegar
Ann and Marc Winthrop
Greg and Barbara Wipf
Bud and Barb Wise
The Ken Wishall Family
Mr. and Mrs. Barry Wolf
Richard and Jane Wolf
Gregg Wolfe/Kaplan, Leaman, and Wolfe Court Reporters
Claire Wolfe
Lawrence and Stacey Wolin
Wolverine World Wide, Inc.
Patricia and Larry Wright
Terry and Dana Wright
Xcoal Energy and Resources
XL Group
XTO Energy
Mr. and Mrs. Michael Yackira
Mr. and Mrs. James L. Yeargan
Yocum Oil Company
Yoh Group
Beverly and Bruce Young
Mary Jeanette Yuengling Charitable Remainder Trust
The Zaltzman Family
Janice and Jason Zeid
Todd and Julianne Zeile
Lauri and Bruce Zessar
Frank and Andrea Ziegler
Zurich Financial Services
In 2007, after having lived with type 1 diabetes for more than 34 years and having lost a grandmother to its complications, Melinda Monier didn’t think she could be any more ready to see an end to the disease. Then she got a heartbreaking phone call: her 28-month-old grandson Rory had also been diagnosed with type 1 diabetes.
As soon as Rory’s parents started a family JDRF Walk team called Rory’s Mission in 2008, Melinda seized the opportunity to kick her JDRF involvement into high gear. She immediately arranged for a Bag of Hope for Rory and became active in her local Louisiana Chapter, participating in the 2008 and 2009 Walks and taking part in an inspirational video for the Gala. Currently, Melinda serves as a committee-at-large member of her chapter’s Board. Melinda is endlessly motivated by seeing how Rory’s parents throw themselves into the cause wholeheartedly, supporting JDRF through a number of fundraising events. Melinda says that “the hope and the faith that a cure will be found in Rory’s lifetime” also helps to guide her extensive commitment.
Recently, Melinda and her husband, Jerry, took their JDRF commitment to the next level by including the foundation in their estate plans. “The reason JDRF is mentioned in our wills is because we feel that they are the best hope for a cure,” she explains. Melinda stresses that “a cure for type 1 diabetes is critical,” especially since she worries that her “two small granddaughters could also be at risk.” Melinda is most heartbroken by seeing children suffer with the disease. “Children should be able to be children,” she says. “They should not have to be concerned with blood sugar highs and lows, carb counting, insulin injections, finger sticks, and all the complications associated with type 1 diabetes.”
Today, Rory is a happy five year old who loves playing sports and is an inspiration to his grandmother. “He loves snow cones,” she says. “He calls me Mim, and one day after a game he said, ‘Mim, you and me, we’re gonna get the sugar-free cones because we have type 1 diabetes.’” As Melinda puts it, “My grandson inspires me everyday. I have become a better diabetic because I have to set an example for him.”
Jdr
F i dO
nO
r s
up
pO
rT
42
Anonymous (46)
Beth Adams
Thomas Anderson
Ann Ansel
Kelly and Mark Anthony
Andrea and Mark Bacik
Angela and Michael Barber
Deborah J. Barrett
Teresa Bath
Ann and Thomas Behan
Jayne Beyer
Skene and Rebecca Black
Robin Bosch
Carol Bradway
Katherine and Rob Burgener
Virginia and Lawrence Capek
Kristen and David Carter
William Cederholm
Lee Clark
Rita Cohen
Cindy Lorenston Cook
Erica and Greg Cowan
Sean Curran
Illa and Kevin Davis
Linda and Bill Dettelback
Jennifer and John Dilling
Lawrence Dolce
Kathi and Bruce Donnor
Dennis and Jo Ann Dworshak
Mary Eckhert
Robert Edelbrock
Allyson and Ruedy Edgington
Jay Ellett
KC England
Jenny and Neill Erdossy
Priscilla Call Essert
Megan and John Farley
Rick Ferguson
Olivia and Grady Foster
Lisa Sailor-Fowler and Bob Fowler
Mary and Terry Franke
Greg Gallant
Chaprell Gazzerro
Lani Gendron
Camden Gooch
Melissa and Michael Gray
Stephen Grieco
James Griffin
Jim Griffith
Gabriella Guazzo
Lori and Jody Hanks
Frances Hansen
Errol Harris
Lisa and Mark Haslam
Eileen and Mike Hendren
Jack Hickethier
John Hipp
Tea Hoffman
Mary Hollock
Donald S. Huddleston
George B. Hutchinson
Rosalind and David Ingber
Dave Johnson
Gloria Jones
Deborah and Steven Jones
Stephanie Jones
Kristen Judd
Laurie and Tom Kane
William Keller
Shirley and Gary Kerkow
Caroline Kinsey
Rachelle and Randal Kline
Lisa and Todd Klumok
Bonnie Kunzel
Teresa and Kevin Lentz
Leigh MacHaffie
Tina Maden
Dr. Ira and Susannah Marks
Patrick McKowen
James McLaughlin
Janice and David Merdgen
Mrs. Charles Monasee
Melinda and Jerry Monier
Deborah Newsome
Jon Nordenberg
Steve Peterson
Dr. Kevin and Becky Pogreba
Earl and Juli Postol
Melissa and Thomas Reedy
Michelle and Frank Reynaud
Shawn Reynolds
Irene and John Ronzia
Kenneth Roosth
The BETA Society recognizes individuals who have included JDRF as a beneficiary in their estate plans. The listing below features BETA Society members who made new planned giving commitments to JDRF in FY2010.
BeTA sOCIeTY MeMBeRs
dO
nO
r s
up
pO
rT
i
Jdr
F
Over the past six years, JDRF has distributed over
50,000 Bags of Hope to children newly
diagnosed with type 1 diabetes.
RESEARCH RESOURCES
RES
ULT
S
43
Jon Rosa
Carol and Walt Rosebrough
Linda and Kreg Rowe
Jennifer and Joel Russell
Dr. and Mrs. Joseph Sansevere
Joshua Sauberman
Paul Schlesinger
Erica and Scott Schuetze
Susan and Dr. Lenny Segal
Dr. and Mrs. Sam Shatkin
Jenny and Tom Sheahan
Marc Sheffler
Ruth and Kevin Shelly
John Shrewsberry and Ereca Miller
Kevin Smith
Elizabeth Squires
Mark Stevens
Judy and Bob Strohl
Judy Summers
Todd R. Teter
Karen and Ted Thielens
Dana Thomas
Suzanne and Todd Turnlund
Holly and Robert Udell
Lynda Ufer
Bob and Meg Van Schoorl
Laura Vartanian
Tania Violette
Allan Wearing
Julie Weiss
Linda and Hank Wells
Marcus Wesche
Charles Wexler and Stephanie Wexler Malone
Mark Whitehead
Shea Wills
Thomas Wood
Janet and Robert Yaroma
A great-great-uncle’s LoveElmer Livingston
Elmer Livingston was a kind but private man. He lived into his 90s, staying active in body and mind until his later years. Before retirement, Elmer made a living buying royalties in the oil business; he saved his earnings and invested them carefully. Though Elmer was a dedicated and meticulous manager of his stocks and wealth, it was his family that was the true center of his world. His nephew Jack explains, “Elmer didn’t show a lot of emotion, but he had a lot of emotion.”
Nowhere is Elmer’s love for his family more evident than in the trust he created, in which he left over $114,000 to JDRF. The impetus behind his generous gift was his two great-grand-nieces, Clara Livingston and Meghan Fisher, each of whom lives extremely successfully with type 1 diabetes. Clara, now 14 – a wonderfully accomplished student, violinist, softball player, and swimmer – was diagnosed at age four. She attended Children’s Congress and since 2002 has participated in her Illinois Chapter’s Walk, for which her family’s team has raised over $100,000. Clara’s mother, Gretchen, who served on the Illinois Chapter’s Board, says, “She’s an amazing kid who’s done an amazing job of managing her diabetes.”
Meghan, 16, is also an outstanding student and athlete: She has won the Oklahoma State Gymnastics competition for her age group three times, twice after her diagnosis at age 14. Meghan’s parents, Bob and Wendi, have become highly involved with their local Tulsa Green Country Chapter, particularly in the Gala. Wendi says that since her diagnosis, “Meghan says she sees herself stronger.”
Elmer would be enormously proud to see his two great-grand-nieces thriving so beautifully today, and to know that his generous contribution is going directly toward improving the lives of Clara, Meghan, and everyone living with type 1 diabetes.
Jdr
F i dO
nO
r s
up
pO
rT
The Juvenile Diabetes Research Foundation International wishes to express its deepest gratitude to the following members of the JDRF family for their generous donations of $10,000 or more to the JDRF Stem Cell Research Fund. These donors, and many others, have provided JDRF with more than $19 million since the Fund’s inception in FY2002. Their vision and leadership ensure that JDRF can continue to vigorously pursue stem cell research, which holds such promise for a cure for type 1 diabetes and its complications.
Co-Chairs: Mary Tyler Moore & s. Robert Levine, M.D.
Anonymous (4)
The Judith and Jean Pape Adams Charitable Foundation
Alagem Capital Group
Susan Alberti AO Hon LLD*
Mrs. Kathleen Albrecht and Mr. Pete McCormick
Andrew Family Charitable Foundation
Helene and Allen Apter
Ares Management LLP
Veronica Atkins
Karen Barfoot*
The Bloom and Mittel Founding Families of the Greater Bay Area Chapter
Quent and Inez Boyken
William K. and Delores Brehm
Broidy Capital
Capital Guardian Trust
Richard and Elizabeth Carrell
Chartwell Charitable Foundation
Dean and Shirley Chenoweth
Clarity Partners
Irene and Seymour Cohen
Comerica Bank
Ken and Sherry Corday
Thomas and Wendy Cramer
Creative Arts Agency
Alison and Richard Crowell
Jaime Davila
Lawrence J. and Florence A. DeGeorge Charitable Trust
Danny DeVito and Rhea Perlman
Eunice L. Dwan 1991 Irrevocable Trust
EMWIGA Foundation
Entertainment Industry Foundation
Joel and Marcia Faber
Allen Feltman and Arlene Jacobs, M.D.
Mr. and Mrs. Simon C. Fireman
First Republic Bank
Marilyn & Dr. Gerald Fishbone
Greg Fisher and Family
The Ella Fitzgerald Charitable Foundation
Jeanine Forman-Ham
The Lauren Gatlin Stem Cell and Beta Cell Research Initiatives Fund
Geffen Foundation
James Gorton
44
sTeM CeLL ReseARCh FuND
dO
nO
r s
up
pO
rT
i
Jdr
F
www.trials.jdrf.org
More than 15,000 people
have registered with JDRF’s Clinical Trials Connection to gain information on
type 1 clinical trials.
RESEARCH RESOURCES
RES
ULT
S
45
Greenberg, Glusker, Fields, Claman and Machtinger
Clay Hammerstein and Family
Michael Heine*
Michael and Loretta Helfant
Stephen and Roey Higgs*
Hille Foundation
Irell and Manella, LLP
Frank and Sophia Jackson*
Robert Wood Johnson IV
Julie and John Johnston
Damien and Yvonne Jordan
Marjorie & Maxwell Jospey, In Memory of Their Daughter, Jane Jospey Cobb
Marjorie & Maxwell Jospey Foundation
WM Keck Foundation
The Kennedy/Marshall Company
Brent Kessel and Britta Bushnell
Taras and Kristen Kihiczak
Laurie and Alec Kouyoumdjian
Gilda and Murray Lappe
Latham & Watkins, LLP
Eason and Ellen Leake
The Lee Family Fund
Lewis-Sebring Family Foundation
Richard and Jacqueline Loynd
The Joseph D. Maio Scholarship Fund
Sharon and Tom Malloy
Alfred Mann
Fred and Susan Mardell
Andy and Terry Marx Foundation
Douglas Matheson-Illinois Tool Works
Helen and William Mazer Foundation
Brian McCarthy
Michael and Kimberly McClain
Charles and Aniela McCool
In Honor of Allison McDonough
McDonough Family Foundation
The Giles W. and Elise G. Mead Foundation
Marianne and G. Allen Mebane
Shelly and Ira Meister
Medtronic MiniMed
Steven G. Mihaylo
Mr. and Mrs. Gary Millican, In Honor of Alexander Millican and In Memory of Roy E. Millican, Jr.
Mary Tyler Moore and S. Robert Levine, M.D.
Jim and Susan Nelson
Nicholl Family Foundation, Inc.
O’Melvany and Meyers
Bert C. O’Neal, In Honor of Lisa and Jack Reed and Elizabeth Shannon
In honor of Kathy & Mark Papermaster, Kathy & Steve Papermaster and Gail Papermaster & Dave Mattson
Lorna and Gary Pederson
Paramount Pictures
Lea and Barry Porter
PR 21
Kay and Jay Proops
Mitchell and Nina Quaranta
Steve and Anne Rader
Mr. and Mrs. Jack Reed, Jr.
Remy Investors
Jamie and Anthony Ressler
In Honor of Mr. and Mrs. David I. Roos, Jr. and Family, In Memory of Debbie Roos Hoppenfeld
Jan M. Roswig
Sheila Royles*
Renee and Robert T. Samuels
Scudder Investments and Deutsche Asset Management
In Honor of Elizabeth O’Neal Shannon
Elizabeth O’Neal Shannon and Jack Herbert Shannon
In Honor of Mrs. JoAnn Shull and In Memory of Her Daughter, Candy
Mrs. JoAnn Shull
Mr. James M. Shure and Family
Kelly and David Siegel
Reagan Silber-Edge TV
Sandra and Alan Silvestri
Victoria Mann Simms
Skadden Arps
Marianne and Roy C. Smith
Sony Pictures Entertainment
Brenda and James Souers
In Honor of Barry and Mimi Sternlicht
Jim and Susan Stuart, Jr.
Tiscornia Foundation
TransAmerica
Trench Shoring Co.
Jami and Nicolaus Von Heidegger
Warner Brothers Pictures
Casey Wasserman
Charles and Mary Jane Wick
Cynthia Wick and Channing Gibson
Doug Wick and Lucy Fisher
David and Terry Wohlberg
Mr. and Mrs. William T. Young, Jr.
Anne and Allen Zaring
Julianne and Todd Zeile
Robert Zemeckis – Image Movers
Donor to the Nucleus Fund
Jdr
F i dO
nO
r s
up
pO
rT
Names in gold indicate donors making gifts during FY2010Names in boldface indicate a donor to the Nucleus Fund *Australia
Nearly every JDRF chapter in the
U.S. provides trained mentors to assist people with type 1
diabetes.
RES
EAR
CH RESOURCES RESULTS
46
JDRF is pleased to recognize the following donors for their generous investments in specific JDRF-funded research studies. By helping to fund JDRF’s research priority areas, these donors play a critical role in aiding our efforts to improve the lives of – and ultimately find a cure for – people with type 1 diabetes. The following are named grants that received funding during FY2010.
NAMeD gRANTs
dO
nO
r s
up
pO
rT
i
Jdr
F
Estate of Helene Alley in Memory of Theodore Whitlock and Theodore Whitlock, Jr.
Pancreatic Stem Cells
Derek Van der Kooy, Ph.D.
University of Toronto, Toronto, CAN
In Honor of Jonathan P. Altman Research Grant Award
TXNIP, A Novel Therapeutic Target for Type 1 Diabetes
Anath Shalev, M.D.
University of Wisconsin – Madison, Madison, WI, USA
Diane Gay, Mike & Tamra Gay In Honor of Parker Gay & in Memory of His Grandfather, Francis V. Gay
nPod Coordinating Center
Mark Atkinson, Ph.D.
University of Florida, Gainesville, FL, USA
Estate of Bernard Jaffee
Involvement of Heparanase in Diabetic Nephropathy
Israel Vlodavsky, Ph.D.
Technion – Israel Institute of Technology, Haifa, ISR
In Honor of Ahmed Mahfooz Latif
Regulation of CD4 T cell Islet Entry
Dario Vignali, Ph.D.
St. Jude Children’s Research Hospital, Memphis, TN, USA
Lewis–Sebring Family Foundation
In support of Dr. Alexander Chervonsky
University of Chicago, Chicago, IL, USA
Vickie & Robert Mercer
Novel Pathways to Expansion of Functional Beta Cell Mass
Christopher B. Newgard, Ph.D.
Duke University Medical Center, Durham, NC, USA
The Proctor & Gamble Company Career Development Award
Regulatory T cells, Immune Privilege and Islet Allograft Tolerance
Zhenhua Dai, M.D., Ph.D.
University of Texas Health Center, Tyler, TX, USA
Rancho Santa Fe Women’s Fund
Drug Development for Beta Cell Regeneration
Fred Levine, M.D.
University of California San Diego, San Diego, CA, USA
In Memory of Lisl Schuhmann
Accomplishing Type 1 Diabetes Immune Regulation in the Pancreas
Manuela Battaglia, Ph.D.
Fondazione Centro San Raffaele del Monte Tabor, Milano, ITA
In Honor of Tops Markets, LLC
A Future Without Diabetes Career Development Award
Molecular Profile of the Human Diabetic Kidney Disease
Katalin Susztak, M.D., Ph.D.
Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA
The Louis Vance Family In Honor of Kathryn Vance Research Grant
Targeted Expression of Insulin to Intestinal Encocrine Cells
Timothy Kieffer, Ph.D.
University of British Columbia, Vancouver, BC, CAN
The Wattles Family Foundation in Honor of Conner Wattles
Cell Fate Potential of Putative Progenitor Cells from Telomerase Tg Mice
David Breault, M.D., Ph.D.
Children’s Hospital, Boston, MA, USA
The Sybil and David Yurman Postdoctoral Fellowship Award
Identifying Urinary Biomarkers of Diabetic Nephropathy
Maryam Afkarian, M.D., Ph.D.
Massachusetts General Hospital (The General Hospital Corp.), Boston, MA, USA
www.jdrf.org/satrequest
JDRF’s School Advisory Toolkit has been downloaded by over 10,000 people since its launch in
February 2008.
RESEARCH RESOURCES
RES
ULT
S
47
Jdr
F i Fina
nC
iaL r
ep
Or
T
fInancIal rePorT
48
62%
60%
7%
22%
20%
6%
11%
12%
Fin
an
Cia
L r
ep
Or
T i
Jd
rF
82%
FUNCTIONAL EXPENSES $191.0Mfor the year 2010
n Management & General $13.0M
n Fundraising $21.4M
Research & Education Programs $156.6M
n Public Education $38.7M
n Research Support $117.9M
PUBLIC SUPPORT AND REVENUE $207.1Mfor the year 2010
n Contributions $45.3M
n International Affiliate Transfers $24.7M
n Revenue $13.5M
n Special Events, Including Walk (net) $123.6M
Independent Auditors’ Report
The Board of DirectorsThe Juvenile Diabetes Research Foundation International:
We have audited the accompanying statements of financial position of The Juvenile Diabetes Research Foundation International (the
Foundation) as of June 30, 2010 and 2009, and the related statements of activities, functional expenses, and cash flows for the years
then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide
a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Juvenile
Diabetes Research Foundation International as of June 30, 2010 and 2009, and the changes in its net assets and its cash flows for the
years then ended in conformity with U.S. generally accepted accounting principles.
New York, New YorkOctober 4, 2010
sTATeMeNTs OF FINANCIAL pOsITION
The Juvenile Diabetes Research Foundation International June 30, 2010 and 2009
49
See accompanying notes to financial statements.
Jdr
F i Fina
nC
iaL r
ep
Or
T
LIABILITIES AND NET ASSETS
Liabilities
Accounts payable and accrued expenses $ 12,610 7,323
Liabilities related to split-interest agreements 2,554 2,598
Deferred special events revenue 4,524 4,346
Research grants payable (note 9) 152,664 180,152
Total liabilities 172,352 194,419
Commitments and contingencies (note 10)
Net assets (accumulated deficit):
Unrestricted 466 (20,868)
Temporarily restricted (note 11) 25,675 31,122
Permanently restricted (note 11) 5,414 5,208
Total net assets 31,555 15,462
Total liabilities and net assets $ 203,907 209,881
(in thousands) 2010 2009
ASSETS
Cash and cash equivalents $ 23,118 42,311
Investments (note 3) 146,062 134,535
Accrued income 5,081 3,770
Contributions receivable, net (note 6) 23,094 23,467
Prepaid expenses and other assets 2,792 3,568
Fixed assets, net (note 7) 3,760 2,230
Total assets $ 203,907 209,881
See accompanying notes to financial statements.
sTATeMeNTs OF ACTIVITIes
50
The Juvenile Diabetes Research Foundation International Years ended June 30, 2010 and 2009
Fin
an
Cia
L r
ep
Or
T i
Jd
rF
ExPENSES (NOTE 5):
Program services:
Research support, net (note 9) 117,920 — — 117,920 109,912 — — 109,912
Public education 38,657 — — 38,657 36,072 — — 36,072
156,577 — — 156,577 145,984 — — 145,984
Supporting services:
Management and general 13,001 — — 13,001 11,930 — — 11,930
Fund-raising 21,417 — — 21,417 19,665 — — 19,665
34,418 — — 34,418 31,595 — — 31,595
Total expenses 190,995 — — 190,995 177,579 — — 177,579
Change in net assets 21,334 (5,447) 206 16,093 (29,983) (4,102) 51 (34,034)
Net assets (accumulated deficit) at beginning of year (20,868) 31,122 5,208 15,462 9,115 35,224 5,157 49,496
Net assets (accumulated deficit) at end of year $ 466 25,675 5,414 31,555 (20,868) 31,122 5,208 15,462
(in thousands) 2010 2009
UnrestrictedTemporarily
RestrictedPermanently
Restricted Total UnrestrictedTemporarily
RestrictedPermanently
Restricted Total
PUBLIC SUPPORT AND REVENUE:
Public support and revenue:
Contributions $ 31,517 13,763 — 45,280 32,509 8,136 — 40,645
Special events:
Proceeds 149,003 — — 149,003 147,140 — — 147,140
Direct donor benefits (25,430) — — (25,430) (27,095) — — (27,095)
Contributions from affiliates (note 8) 24,693 — — 24,693 18,567 — — 18,567
Total public support 179,783 13,763 — 193,546 171,121 8,136 — 179,257
Revenue (loss):
Investment return (loss) (note 3) 13,104 8 206 13,318 (36,390) 5 51 (36,334)
Other 224 — — 224 622 — — 622
Total revenue (loss) 13,328 8 206 13,542 (35,768) 5 51 (35,712)
Net assets released from restrictions 19,218 (19,218) — — 12,243 (12,243) — —
Total public support and revenue $ 212,329 (5,447) 206 207,088 147,596 (4,102) 51 143,545
See accompanying notes to financial statements.
sTATeMeNTs OF FuNCTIONAL expeNses
51
The Juvenile Diabetes Research Foundation International Years ended June 30, 2010 and 2009
Jdr
F i Fina
nC
iaL r
ep
Or
T
(in thousands) 2010
PROGRAM SERVICES SUPPORTING SERVICES
Research support
Public education Total
Management and general Fund-raising Total
Total expenses
Research grants, net (note 9) $ 107,547 — 107,547 — — — 107,547
Payroll and related expenses 6,701 25,591 32,292 8,656 14,069 22,725 55,017
Printing and promotional expenses 284 2,086 2,370 489 2,019 2,508 4,878
Office rent and related expenses, including depreciation and amortization 1,624 6,305 7,929 2,548 3,329 5,877 13,806
Meetings and conferences 786 2,045 2,831 380 782 1,162 3,993
Professional services 869 995 1,864 379 390 769 2,633
Miscellaneous 109 1,635 1,744 549 828 1,377 3,121
Total functional expenses 117,920 38,657 156,577 13,001 21,417 34,418 190,995
Percentage of total functional expenses 61.74% 20.24% 81.98% 6.81% 11.21% 18.02%
Costs of direct benefits to donors 25,430
Total expenses and costs of direct benefits to donors $ 216,425
2009
PROGRAM SERVICES SUPPORTING SERVICES
Research support
Public education Total
Management and general Fund-raising Total
Total expenses
Research grants, net (note 9) $ 100,870 — 100,870 — — — 100,870
Payroll and related expenses 6,045 22,965 29,010 7,798 12,543 20,341 49,351
Printing and promotional expenses 242 2,560 2,802 523 1,936 2,459 5,261
Office rent and related expenses, including depreciation and amortization 1,190 5,776 6,966 2,173 2,822 4,995 11,961
Meetings and conferences 722 1,665 2,387 451 1,122 1,573 3,960
Professional services 776 1,648 2,424 509 634 1,143 3,567
Miscellaneous 67 1,458 1,525 476 608 1,084 2,609
Total functional expenses 109,912 36,072 145,984 11,930 19,665 31,595 177,579
Percentage of total functional expenses 61.90% 20.31% 82.21% 6.72% 11.07% 17.79%
Costs of direct benefits to donors 27,095
Total expenses and costs of direct benefits to donors $ 204,674
(in thousands) 2010 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Change in net assets $ 16,093 (34,034)
Adjustments to reconcile change in net assets to net cash used in operating activities:
Net (appreciation) depreciation in fair value of investments (11,002) 40,027
Depreciation and amortization 1,989 960
Changes in operating assets and liabilities:
Accrued income (1,311) 1,608
Contributions receivable 373 3,109
Prepaid expenses and other assets 776 (574)
Accounts payable and accrued expenses 5,287 (4,643)
Split-interest agreements (44) (282)
Deferred special events revenue 178 (260)
Research grants payable (27,488) (21,003)
Net cash used in operating activities (15,149) (15,092)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets (3,519) (1,381)
Purchase of investments (24,014) (14,863)
Proceeds from sale of investments 23,489 53,046
Net cash (used in) provided by investing activities (4,044) 36,802
Change in cash and cash equivalents (19,193) 21,710
Cash and cash equivalents at beginning of year 42,311 20,601
Cash and cash equivalents at end of year $ 23,118 42,311
sTATeMeNTs OF CAsh FLOWs
52
See accompanying notes to financial statements.
The Juvenile Diabetes Research Foundation International Years ended June 30, 2010 and 2009
Fin
an
Cia
L r
ep
Or
T i
Jd
rF
NOTes TO FINANCIAL sTATeMeNTs
53
June 30, 2010 and 2009 (Amounts in thousands)
1. ORGANIzATIONThe mission of The Juvenile Diabetes Research Foundation International (the Foundation) is to find a cure for diabetes and its complications through the support of research.
The Foundation solicits contributions from the public and engages in various fund rais-ing activities. Funds raised are used to support Type 1 diabetes research. In addition, the Foundation engages in advocacy efforts aimed at increasing federal funding of Type 1 dia-betes research.
The financial statements of the Foundation include the accounts of the Foundation and its Chapters located throughout the United States. The Foundation has international affiliates located in Canada, Australia, the United Kingdom, and a number of other countries. The financial statements of those organizations are not included in the accompanying financial statements since the Foundation does not exercise control over the management and op-erations of the international affiliates.
The Foundation is a not for profit organization exempt from federal income taxes un-der Section 501(c)(3) of the Internal Revenue Code, organized under the laws of the Commonwealth of Pennsylvania.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESA. BASIS OF PRESENTATIONThe Foundation’s financial statements are prepared on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board (FASB) for external financial reporting by not for profit organizations. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:
Unrestricted Net Assets—Net assets that are not subject to donor imposed restrictions.
Temporarily Restricted Net Assets—Net assets subject to donor imposed restric-tions that will be met either by actions of the Foundation or by the passage of time.
Permanently Restricted Net Assets—Net assets subject to donor imposed re-strictions, which stipulate that the principal be maintained permanently by the Foundation, but permit the Foundation to expend part or all of the income and gains derived there from.
Revenues and gains and losses on investments and other assets are reported as changes in unrestricted net assets unless limited by explicit donor imposed restrictions or by law. Expenses are reported as decreases in unrestricted net assets.
When a time restriction ends or a purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions.
B. CONTRIBUTIONSContributions, including unconditional promises to give (pledges), are reported as rev-enues in the period received or pledged. Contributions with purpose or time restrictions that are not met in the same reporting period as received are reported as increases in temporarily restricted net assets and are reclassified to unrestricted net assets when the purpose or time restrictions are met. Contributions subject to donor imposed stipulations that the corpus be maintained permanently are recognized as increases in permanently restricted net assets.
Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions of as-sets other than cash are recorded at their estimated fair value. Contributions expected to be received after one year are discounted at a risk adjusted rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor imposed restrictions, if any, on the contribution.
Contributions received for future special events, primarily walk events, are recorded as deferred revenue and are recognized as revenue in the fiscal year the event takes place, which is generally within one year.
The Foundation administers two types of split interest agreements – Charitable Gift Annuities and Charitable Remainder Trusts. With Charitable Gift Annuities, the Foundation receives cash or marketable securities from a donor in exchange for an annuity to be distributed for a fixed amount over the lifetime or lifetimes of the donor or other benefi-ciaries. Upon the death of the annuitant or survivor of the annuitants, the Foundation is entitled to full use of the remainder. With Charitable Remainder Trusts administered by the Foundation, the Foundation receives donated assets as trustee under a trust agree-ment established by the donor in exchange for an income stream to be distributed to the donor and/or other beneficiaries over a specified period of time. The distribution to the donor or other beneficiaries may be a fixed dollar amount (an annuity trust) or percent-age of the fair value of the trust as determined annually (unitrust). Upon the termination of the trust, the Foundation is entitled to full use of the remainder. For both Charitable Gift Annuities and Charitable Remainder Trusts, a related liability is recorded for the ac-tuarially determined present value of the obligation to the annuitant or annuitants. The discount rates used to calculate the liability range between 2.6% and 8.2% at June 30, 2010. For Charitable Gift Annuities, the assets received are held as general assets of the Foundation, and the annuity liability is a general obligation of the Foundation.
C. CASH AND CASH EQUIVALENTSCash equivalents consist of money market accounts, demand notes, savings accounts, and certificates of deposit purchased with original maturities of three months or less, except for such instruments purchased by the Foundation’s investment managers as part of their investment strategies.
D. INVESTMENTSThe Foundation’s investments, including assets related to split interest agreements, are reported at fair value based upon quoted market prices or, with respect to hedge funds and convertible preferred stock, at estimated fair value. The estimated fair value of hedge funds, as a practical expedient, is the net asset value as provided by the investment managers, and evaluated for reasonableness by the Foundation. The fair value of the convertible preferred stock of a private company is estimated by the Foundation based upon audited financial statements and other information provided by the company. Due to the inherent uncertainties of these estimates, these values may differ from the values that would have been used had a ready market existed for such investments.
E. FIxED ASSETSFixed assets, which consist of furniture, equipment, and leasehold improvements, are recorded at cost. Depreciation is provided on a straight line basis over the estimated useful lives of the assets, which approximate three to ten years for furniture and equip-ment. Leasehold improvements are amortized on a straight line basis over the shorter of the life of the asset or the lease term.
F. FAIR VALUE OF FINANCIAL INSTRUMENTSFinancial instruments are defined to include: cash and cash equivalents, investments, receivables, assets related to split interest agreements, accounts payable, and liabilities related to split interest agreements. The fair value of investments is discussed in note 3. The carrying amount of the Foundation’s remaining financial instruments approximates fair value.
G. ALLOCATION OF JOINT COSTSThe Foundation allocates joint costs between fund raising and program services or management and general in accordance with Accounting Standards Codification (ASC) No. 958-720, Accounting for Costs of Activities of Not for Profit Organizations and State and Local Governmental Entities That Include Fund Raising.
H. USE OF ESTIMATESThe preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the year. Significant estimates made in the preparation of the financial statements include fair value of alternative investments, net realizable value of contributions receivable, and functional expense allocation. Actual results could differ from those estimates.
I. FUNCTIONAL ALLOCATION OF ExPENSESThe costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly, certain costs have been allocated among the programs and supporting services areas that were benefited.
J. NEW ACCOUNTING STANDARDSIn 2010, the Foundation adopted the disclosure requirements of Accounting Standards Update (ASU) No. 2009 — 12, Fair Value Measurements and Disclosures – Investments in Certain Entities That Calculate Net Asset Value per Share (or its Equivalent), with respect to investments within its scope. The Foundation had adopted the measurement provisions of this guidance in 2009.
In 2010, the Foundation adopted ASU 2009 — 06, Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities, in conjunction with its adoption of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (now included in ASC Subtopic 740 10, Income Taxes – Overall). FASB Interpretation No. 48 addresses the accounting for uncertainties in income taxes recognized in an organization’s financial statements and prescribes a threshold of more-likely-than-not for recognition and derecognition of tax positions taken or expected to be taken in a tax return. There was no significant impact on the Foundation’s financial statements as a result of the adoption of this guidance.
3. INVESTMENTSInvestments at June 30, 2010 and 2009 consisted of the following:
2010 2009Cash and cash equivalents $ 16,000 —Equity mutual funds Domestic 18,626 16,962 Foreign 2,636 2,410Convertible preferred stock 4,934 4,934Fixed income mutual funds Corporate 9,714 28,383 Government 14,565 7,380Hedge funds 79,587 74,466 Total investments $ 146,062 134,535
Included in investments are amounts related to Charitable Gift Annuities and Charitable Remainder Trusts totaling $2,177 and $2,193, respectively, at June 30, 2010 and $1,928 and $2,040, respectively, at June 30, 2009.
Jdr
F i Fina
nC
iaL r
ep
Or
T
54
nOTes TO FinanCiaL sTaTeMenTs continued
The Foundation’s investments are exposed to various risks, such as market and credit risks. Because of the risk associated with such investments, it is possible that change in their values will occur and that such changes could materially affect the Foundation’s financial statements. The Foundation is exposed to credit risk in the event of nonper-formance by the issuers of the fixed income securities. However, the Foundation does not anticipate such nonperformance.
Assets and liabilities reported at fair value are required to be classified within a fair value hierarchy, which gives preference to the use of observable inputs over unobserv-able inputs. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of the fair value hierarchy are as follows:
• Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
• Level 2 inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
• Level 3 inputs are unobservable inputs for the asset or liability.
Most investments classified as Level 2 or 3 consist of shares or units in investment funds as opposed to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of the Foundation’s interest therein, its classifica-tion in Level 2 or 3 is based on the Foundation’s ability to redeem its interest at or near the date of the statement of financial position. If the interest can be redeemed in the near term, the investment is classified in Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or de-gree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.
The following table presents the fair value hierarchy of investments as of June 30, 2010:
Total Level 1 Level 2 Level 3Cash and cash equivalents $ 16,000 16,000 — —Equity mutual funds Domestic 18,626 18,626 — — Foreign 2,636 2,636 — —Convertible preferred stock 4,934 — — 4,934Fixed income mutual funds Corporate 9,714 9,714 — — Government 14,565 14,565 — —Hedge funds 79,587 — 75,138 4,449 Total investments $ 146,062 61,541 75,138 9,383
The following table presents the fair value hierarchy of investments as of June 30, 2009:
Total Level 1 Level 2 Level 3Equity mutual funds $ Domestic 16,962 16,962 — — Foreign 2,410 2,410 — —Convertible preferred stock 4,934 — — 4,934Fixed income mutual funds Corporate 28,383 28,383 — — Government 7,380 7,229 151 —Hedge funds 74,466 — 61,598 12,868 Total investments $ 134,535 54,984 61,749 17,802
Information with respect to the strategies of those investment funds which are re-ported at estimated fair value based upon net asset value per share (or its equivalent) is as follows (amounts included are as of June 30, 2010):Long only global ex U.S. equity securities ($9,908) – includes investments in compa-nies that are believed to have overlooked value as well as event driven stocks selling at discounts to their intrinsic values. Investments are in long positions, predominately in developed markets outside of the United States.Long only emerging markets equity securities ($4,887) – includes investments in companies that are believed to have overlooked value as well as event driven stocks selling at discounts to their intrinsic values. Investments are in long positions, pre-dominately in emerging market countries.Multi-strategy hedge funds ($13,611) – includes investments in funds that pursue multiple investment strategies in an attempt to diversify risks and reduce volatil-ity. Capital allocated to each of the strategies, as well as geographical areas, varies depending on market opportunities.Equity long/short hedge funds ($18,561) – includes investments in funds that invest both long and short in equities. Investments are also made in fixed income securities and funds, depending on market conditions.Distressed debt hedge funds ($7,329) – includes investments in funds that attempt to invest opportunistically in troubled companies. Investments encompass distressed debt, private equity, real estate, high yield bonds, and a number of hedge fund strategies. Real assets ($13,943) – includes investments in liquid energy, real estate, and natural resources equities, as well as investments in commodities.Fixed income securities ($11,348) – includes investments in sovereign and invest-ment grade corporate bonds – both in the United States and globally. Investments also include the most senior debt of riskier, non-investment-grade companies.
The limitations and restrictions on the Foundation’s ability to redeem or sell these investments, as well as the convertible preferred stock, vary by investment. Based upon the terms and conditions in effect at June 30, 2010, the Foundation’s Level 2 and 3 investments can be redeemed or sold as follows: AmountsLess than a month $ 9,908Monthly 10,792Quarterly 54,438Annually 2,225Biannually 2,224More than 2 years 4,934 $ 84,521
The following table presents a reconciliation of Level 3 investments for the years ended June 30, 2010 and 2009: 2010 2009Balance at beginning of year $ 17,802 11,274 Transfer to Level 2 (9,554) — Net realized and unrealized gains 1,135 528 Purchases — 6,000Balance at end of year $ 9,383 17,802
The components of investment return and its classification in the statements of activi-ties for the years ended June 30, 2010 and 2009 were as follows: 2010 Temporarily Permanently Unrestricted restricted restricted TotalInterest and dividends $ 2,280 8 28 2,316Net appreciation 10,824 — 178 11,002 $ 13,104 8 206 13,318
2009 Temporarily Permanently Unrestricted restricted restricted TotalInterest and dividends $ 3,644 5 44 3,693Net (depreciation) appreciation (40,034) — 7 (40,027) $ (36,390) 5 51 (36,334)
Investment expenses relating to investment advisors, managers, and custodians and other bank charges are recorded as reductions to interest and dividend income. Investment expenses totaled $686 and $556 for the years ended June 30, 2010 and 2009, respectively.
4. RETIREMENT PLANThe Foundation has a defined contribution pension plan, which covers substantially all employees. The Foundation’s expense for the years ended June 30, 2010 and 2009 was $994 and $508, respectively.
5. ALLOCATION OF JOINT COSTSIn 2010 and 2009, the Foundation conducted activities, principally direct mail, that in-cluded fund raising appeals as well as program components. The joint costs incurred were allocated as follows:
2010 2009Public education $ 1,599 1,595Management and general 297 314Fund-raising 2,351 2,363 Total $ 4,207 4,272
6. CONTRIBUTIONS RECEIVABLEContributions receivable at June 30, 2010 and 2009 consisted of:
2010 2009Gross contributions receivable, due in: Less than one year $11,942 10,957 One to five years 12,990 14,579 Thereafter 163 372 25,095 25,908Less: Allowance for doubtful accounts (1,344) (1,324) Unamortized discount to present value, at rates ranging from 1.00% to 5.50% (657) (1,117) $ 23,094 23,467
Contributions receivable have been discounted to their present value at the rate at the time the original unconditional promise to give was made.
Fin
an
Cia
L r
ep
Or
T i
Jd
rF
55
7. FIxED ASSETS
Fixed assets at June 30, 2010 and 2009 consisted of:
2010 2009Furniture and equipment $ 5,568 6,010 Leasehold improvements 1,687 2,054 7,255 8,064Less accumulated depreciation and amortization (3,495) (5,834) Fixed assets, net $ 3,760 2,230
8. CONTRIBUTIONS FROM AFFILIATESDuring the years ended June 30, 2010 and 2009, the Foundation received contributions from affiliates as follows:
2010 2009JDRF - Canada $ 15,586 7,908JDRF - Australia 7,202 9,306JDRF - United Kingdom 1,599 1,183JDRF - Greece 37 65JDRF - Denmark 74 —JDRF - Israel 195 105 $24,693 18,567
JDRF Australia’s 2010 and 2009 contributions include $3,457 and $6,116, respectively, funded by the Australian Government as part of the JDRF Islet Transplantation Program (ITP) in Australia. The program, which began in 2007, funds JDRF approved grants at Australian medical and research institutions to address the basic science surrounding preclinical approaches to improve islet transplantation techniques.
JDRF Canada’s 2010 contributions include $7,883 related to a joint funding agreement with the Federal Economic Development Agency for Southern Ontario as part of the JDRF Canadian T1D Clinical Trial Network. The program funds JDRF- approved grants to conduct clinical trials to further the development and/or commercialization of an artificial pancreas for diabetics and to establish a Clinical Trial Network in Southern Ontario in order to facilitate and coordinate the conduct of Phase I and II Clinical Trials.
9. RESEARCH GRANTS PAYABLEResearch grants payable at June 30, 2010 and 2009 consisted of:
2010 2009Amounts expected to be paid in: Less than one year $ 150,420 168,837 One to five years 2,269 11,585 Subtotal 152,689 180,422Less discount to present value, at rates ranging from 1% to 1.71% (25) (270) Total $ 152,664 180,152
Research grant expense is net of any grant refunds, reductions, or terminations. These adjustments were $13,178 and $52,928 for the years ended June 30, 2010 and 2009, respectively.
10. COMMITMENTS AND CONTINGENCIES
A. RESEARCH GRANTSAs of June 30, 2010, there were conditional research grant commitments of $102,453, which will be recognized in the Foundation’s financial statements when the conditions have been substantially met, and are currently estimated to be payable as follows:
2011 $ 73,1852012 27,2122013 1,3082014 748 $102,453
B. LEASESEffective January 1, 1995, the Foundation entered into a 15 year lease agreement for executive office space in New York City. In 2001, the Foundation leased additional office space in the same building. Rent expense for the executive office was $1,605 and $1,369 for the years ended June 30, 2010 and 2009, respectively. The Foundation was also re-imbursed for certain construction costs associated with leasehold improvements. The leasehold improvements and a corresponding deferred credit were recorded in 1995, both of which were amortized on a straight line basis over the term of the lease, which expired on December 31, 2009. The Foundation did not renew this lease.
On August 3, 2009, the Foundation entered into a new lease agreement and relocat-ed its national headquarters during December 2009. The new lease commenced on September 1, 2009 for a 10 year term. Annual rent will be $1,269, increasing to $1,353 after the fifth year. Rent expense is recognized on a straight-line basis and, accordingly, a deferred rent credit has been recorded. At June 30, 2010, a credit of approximately $1,000 is included in accounts payable and accrued expenses.
The Foundation is also obligated under various leases for space occupied by certain Chapters. Rent expense including maintenance costs for the Chapters was $3,687 and $3,744 for the years ended June 30, 2010 and 2009, respectively.
Rental commitments for all leases are as follows:
2011 $ 5,2652012 4,6802013 3,5332014 2,4882015 2,0992016 1,827Thereafter 5,130 $ 25,022
C. LINE OF CREDITOn February 19, 2010, the Foundation entered into an agreement with JP Morgan Chase for an unsecured line of credit in the aggregate amount of $10 million. The term of the agreement expires January 29, 2011. The line of credit was unused as of June 30, 2010.
11. NET ASSETS
A. TEMPORARILY RESTRICTED NET ASSETSAt June 30, 2010 and 2009, temporarily restricted net assets were available for the fol-lowing purposes:
2010 2009Future periods, principally contributions receivable and split-interest agreements $ 24,319 29,733Diabetes Care Coalition program (know your A1C) — 1,014Various research projects 1,356 375 $ 25,675 31,122
B. PERMANENTLY RESTRICTED NET ASSETSAt June 30, 2010 and 2009, the investment return derived from permanently restricted net assets was expendable to support:
2010 2009General activities $ 1,576 1,576Research projects: Artificial Pancreas Project 2,000 2,000 Virginia Mason Research Center 1,838 1,632 $ 5,414 5,208
The Foundation’s endowment consists of four individual donor restricted endow-ment funds established for a variety of purposes. The Foundation has interpreted Pennsylvania law as requiring the preservation of the fair value of the original gift as of the gift date of the donor restricted endowment funds absent explicit donor stipu-lations to the contrary. As a result of this interpretation, the Foundation classifies as permanently restricted net assets (a) the original value of gifts to the permanent en-dowment and (b) accumulations of investment returns to the permanent endowment made in accordance with the direction of the applicable donor gift instrument, when applicable. The four endowment funds are invested in fixed income mutual funds. The Foundation has no board designated endowment funds.
The following tables present the changes in the Foundation’s donor restricted endow-ment funds for the years ended June 30, 2010 and 2009: 2010 Temporarily Permanently Unrestricted restricted restricted TotalEndowment net assets at June 30,2009 $ — — 5,208 5,208Investment income 397 — 28 425Net appreciation (realized and unrealized) 495 — 178 673Appropriation for expenditure (892) — — (892)Endowment net assets at June 30, 2010 $ — — 5,414 5,414
2009 Temporarily Permanently Unrestricted restricted restricted TotalEndowment net assets at June 30,2008 $ — — 5,157 5,157Investment income 626 — 44 670Net appreciation (realized and unrealized) 20 — 7 27Appropriation for expenditure (646) — — (646)Endowment net assets at June 30, 2009 $ — — 5,208 5,208
12. SUBSEQUENT EVENTSIn connection with the preparation of the financial statements, the Foundation evalu-ated subsequent events through October 4, 2010, which was the date the financial statements were available for issuance, and concluded that no additional disclosures are required.
Jdr
F i Fina
nC
iaL r
ep
Or
T
ChApTeRs & AFFILIATes
56
Ch
ap
Ter
s &
aFF
iLia
Tes
i
Jd
rF
JDRF has over 100 locations worldwide, including chapters and branches active throughout the United States and affiliates in eight countries. JDRF chapters and affiliates host Walks, Galas, and other fundraising events and programs to support the JDRF mission. They also offer support, guidance, and a sense of community for people with type 1 diabetes and their families. Please visit www.jdrf.org for information about JDRF activities near you.
AlabamaAlabama Chapter, Birmingham
ArizonaDesert Southwest Chapter, PhoenixSouthern Arizona Branch, Tucson
ArkansasGreater Arkansas Chapter, Little RockNorthwest Arkansas Branch,
Fayetteville
CaliforniaGreater Bay Area Chapter, San FranciscoInland Empire Chapter, RiversideLos Angeles Chapter, Los AngelesNorthern California Inland Chapter,
SacramentoOrange County Chapter, IrvineSan Diego Chapter, San Diego
ColoradoColorado Springs Branch,
Colorado SpringsRocky Mountain Chapter, Denver
ConnecticutFairfield County Chapter, NorwalkGreater New Haven Chapter, HamdenNorth-Central Connecticut/Western
Massachusetts Chapter, Farmington
DelawareDelaware Branch, Wilmington
District of ColumbiaCapitol Chapter, Washington, DC
FloridaCentral Florida Chapter,
Altamonte SpringsFlorida Suncoast Chapter, SarasotaGreater Palm Beach County Chapter,
West Palm BeachNorth Florida Chapter, JacksonvilleSouth Florida Chapter, Ft. LauderdaleTampa Bay Chapter, St. Petersburg
GeorgiaGeorgia Chapter, Atlanta
HawaiiHawaii Chapter, Honolulu
IllinoisIllinois Chapter, Chicago
IndianaIndiana State Chapter, IndianapolisNorthern Indiana Branch, South Bend
IowaEastern Iowa Chapter, Cedar RapidsGreater Iowa Chapter, Johnston
KentuckyKentuckiana Chapter, Louisville
LouisianaLouisiana Chapter, Baton RougeNew Orleans Branch, New Orleans
MarylandMaryland Chapter, Linthicum
MassachusettsNew England/Bay State Chapter,
Wellesley
MichiganMetro-Detroit/Southeast Michigan
Chapter, SouthfieldMichigan Great Lakes West Chapter,
Grand Rapids
MinnesotaMinnDakotas Chapter, Bloomington
MississippiMississippi Chapter, Jackson
MissouriKansas City Chapter, Kansas CityMetro-St. Louis/Greater Missouri
Chapter, St. Louis
NebraskaLincoln Chapter, LincolnOmaha Council Bluffs Chapter,
Omaha
NevadaNevada Chapter, Las VegasNorthern Nevada Branch, Reno
New HampshireNorthern New England Branch,
Manchester
New JerseyCentral Jersey Chapter, ShrewsburyMid-Jersey Chapter, East BrunswickNorthern New Jersey/Rockland County
Chapter, Englewood CliffsSouth Jersey Chapter, Cherry Hill
New MexicoNew Mexico Branch, Albuquerque
New YorkCentral New York Chapter, LiverpoolGreater Adirondack Region Branch,
Glens FallsHudson Valley Branch, Wappingers FallsLong Island Chapter, MelvilleNew York City Chapter, New York CityBrooklyn/Queens Branch, New York CityStaten Island Branch, New York CityNortheastern New York/Capital Region
Chapter, East GreenbushRochester Chapter, RochesterWestchester County Chapter,
White PlainsWestern New York Chapter, Amherst
North CarolinaCharlotte Chapter, CharlottePiedmont Triad Chapter, GreensboroTriangle/Eastern North Carolina
Chapter, Raleigh
OhioGreater Cincinnati Chapter, CincinnatiGreater Dayton Chapter, DaytonMid-Ohio Chapter, ColumbusNortheast Ohio Chapter, IndependenceAkron/Canton Branch, IndependenceNorthwest Ohio Branch, Toledo
OklahomaCentral Oklahoma Chapter,
Oklahoma CityTulsa Green Country Chapter, Tulsa
OregonOregon/Southwest Washington
Chapter, Portland
PennsylvaniaCentral Pennsylvania Chapter, LemoyneEastern Pennsylvania/Delaware
Chapter, Bala CynwydEast-Central Pennsylvania Branch,
Bala CynwydNorthwestern Pennsylvania Branch,
ErieWestern Pennsylvania Chapter,
Pittsburgh
Rhode IslandRhode Island Branch, Warwick
South CarolinaPalmetto Chapter, ColumbiaWestern Carolinas Chapter, Greenville
TennesseeEast Tennessee Branch, KnoxvilleMiddle Tennessee Chapter, BrentwoodWest Tennessee Branch, Collierville
TexasAustin Chapter, AustinGreater Dallas Chapter, DallasGreater Ft. Worth/Arlington Chapter,
Ft. WorthHouston Gulf Coast Chapter, HoustonPanhandle Branch, AmarilloSouth-Central Texas Chapter,
San Antonio
UtahUtah Chapter, Salt Lake City
VirginiaCentral Virginia Chapter, RichmondGreater Blue Ridge Chapter, RoanokeTidewater Chapter, Virginia Beach
WashingtonInland Northwest Branch, SpokaneJDRF Northwest Chapter, SeattleSeattle Guild, SeattleSouth Sound Branch, Seattle
West VirginiaWest Virginia Branch, Charleston
WisconsinNortheast Wisconsin Chapter, MenashaSoutheastern Wisconsin Chapter,
WauwatosaWestern Wisconsin Chapter, Madison
JDrf affiliates
JDRF AustraliaSt. Leonards, NSW
JDRF CanadaMarkham, Ontario
JDRF DenmarkCopenhagen
JDRF GermanyHeidelberg
JDRF IndiaSalt Lake, Kolkata
JDRF IsraelTel Aviv
JDRF MexicoMexico City
JDRF United KingdomLondon
59
fY2010 board of DirectorsDiane Adams
Fernando Aguirre
Dick Allen
Shannon Allen
Richard K. Bonness
John Brady
Mary Elizabeth Bunzel
Mitchell H. Caplan
Dayton Coles
Cynthia Ford
Chip Halverson
Michael Hendren
Robert R. Hindle
Steve Hitchins
Judy M. Hunt
Francis J. Ingrassia
Robert Wood Johnson IV
Richard Kirkland
Ellen Leake
Richard Levy
John Madden
James F. McDonald
Patrick McFeeley
Leo F. Mullin
David W. Nelms
George Nethercutt
Nettleton S. Payne, M.D.
David Rehr
Lewis R. Runnion
Glen E. Tullman
Michael L. White
William T. Young, Jr.
Anne Zaring
Ex officio: James C. Tyree
fY2010 board of chancellorsSusan Alberti AO Hon LLD
Don Aron
Robert Auerbach
Aubrey W. Baillie
Gordon D. Barker, R.Ph.
Maureen Barunas
Joan Beaubaire
Crandall Bowles
Erskine Bowles
Max C. Chapman, Jr.
Sanford Cloud, Jr.
Judi Cochran
Ross A. Cooley
Don Corrao
Lee Ducat
Samuel D. Ewing, Jr.
Gerald Fishbone, M.D.
Joseph Gardner, Ph.D.
Eileen Gelick
Robert D. German, Esq.
David Glusman
Krayna Golfman
Marilyn Gomm
William Graves
Roslyn Greenspon
Eric Harkna
Margaret Conn Himelfarb, M.P.H.
Michael J. Hopkins, Esq.
Terry A. Jackson
Fran Jacoby
Ardy Johnson
Dave Johnson
Larry King
Robert N. Klein II
Anne Lacey
Joann Leatherby, Esq.
Jan Leeper
Stephen Leeper, D.D.S.
S. Robert Levine, M.D.
Carol Lurie
James M. Lurie, Esq.
John J. McDonough
Steven M. Merdinger
Mollie Miller
Penny Moseley
Leah Mullin
J. Richard Munro
Katharine S. Overlock
Willard J. Overlock, Jr.
Penn Payne, Esq.
Margery D. Perry
Gail Pressberg
Sandra Puczynski, Ph.D.
Charles J. Queenan III
Kenneth M. Rich
Mark Rubenstein
Steven T. Ruby, M.D.
Pam Sagan
Bob Samuels
Alyce Satsky
Helaine Shiff
Sandra D. Silvestri
Adam Singer
Harold Smethills
Roy C. Smith
Emily Spitzer
James Stuart Jr.
James C. Tyree
Peter Wilson
Anne Zaring
senior staffPresident and Chief Executive Officer Jeffrey Brewer
Chief Human Resources Officer Gerri Feemster Bostick, SPHR
Executive Vice President, Development Mania Boyder
Vice President, Research Darlene Deecher, Ph.D.
Senior Vice President, Scientific Affairs Robert A. Goldstein, M.D., Ph.D.
Assistant Vice President, Cure Therapies Julia Greenstein, Ph.D.
Senior Vice President, Strategic Alliances Karin Hehenberger, M.D., Ph.D.
Chief Scientific Officer Richard A. Insel, M.D.
Vice President, Internal Audit Gil King
Vice President, Individual, Major and Planned Giving Jamie Klobuchar
Assistant Vice President, Treatment Therapies Aaron Kowalski, Ph.D.
Vice President, Business Development Michael Malekoff
Vice President, Government Relations Cynthia Rice
Senior Vice President, Marketing and Communications Claire Schultz
Chief Financial Officer & Assistant Treasurer Edward Sebald
Chief Operating Officer Lawrence A. Soler, Esq.
Chief Information Officer James Szmak
DIReCTORs, ChANCeLLORs & seNIOR sTAFF
Produced by Torrisi Design Associates, Inc. NYC
26 Broadway, 14th Floor New York, NY 10004 800-533-CURE 212-785-9500 www.jdrf.org
Top Related